Methods for regulating gene expression by transcription factor-chemically induced proximity (TF-CIP)
Patent Information
- Application Number
- JP2023527379
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-06
- Filing Date
- 2021-11-05
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods for regulating gene expression in cells face challenges due to unpredictability caused by unintended interactions between biological components, particularly transcription factors, making precise and predictable gene expression difficult to achieve without genetic modification.
The use of a transcription factor-proximity chemical inducer (TF-CIP) system that links an endogenous anchored transcription factor to a second transcriptional regulator, modulating gene transcription without genetic modification, by inducing proximity through a chemical linker.
This approach allows for precise and efficient regulation of gene expression, enhancing or reducing transcription of target genes, with potential applications in therapeutics, diagnostics, and biotechnological processes, including the treatment of various cancers and genetic disorders.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] Government rights This invention was made with government support under Contract CA163915, granted by the National Institutes of Health. The government has certain rights in this invention.
[0002] Cross-reference of related applications In accordance with Section 119(e) of the United States Patent Act, this application claims priority to the filing date of U.S. Provisional Patent Application No. 63 / 110,575, filed on November 6, 2020, the disclosure of which is incorporated herein by reference.
[0003] Introduction The control and regulation of gene expression is becoming increasingly important in a wide range of fields, including but not limited to gene therapy, synthetic biology, facility management, environmental remediation, bacterial and microbial management, and synthetic gene circuits. Gene expression regulation holds great potential to revolutionize therapeutics, animal models, and biotechnological processes, and is useful for integrating multiple input signals for cell-based therapies and animal model development. Despite recent rapid advances, precise control of gene expression remains a challenge due to unpredictability resulting from unintended interactions between biological components such as transcription factors. The fundamental goal of cell engineering is to predictably and efficiently express genes under precise control at desired levels. Such genetically engineered cells hold immense potential for advancements in therapeutics, diagnostics, animal models, and biotechnological processes.
[0004] To date, various gene regulation techniques have been developed to control gene expression in cells. Such gene regulation techniques include RNA interference, DNA editing and expression, and compounds that repress, enhance, or modify gene expression. These can be in the form of RNA, DNA, or proteins and can be introduced into cultured cells by direct application to the culture medium, lipofection, electroporation, or viral transduction.
[0005] However, due to the broad applicability of gene regulation to both research and therapeutic applications, there is ongoing interest in developing new methods for regulating the transcription of target genes in cells, particularly new methods for regulating gene expression without gene modification. [Overview of the Initiative]
[0006] overview A method is provided for regulating the transcription of a target gene within a cell without gene modification, and this method may be in vitro or in vivo. Embodiments of this method utilize a transcription factor-proximity chemoinducer (TF-CIP) system to regulate, for example, enhance or reduce the transcription of a target gene within a cell. Embodiments of this method involve providing a proximity chemoinducer (CIP) within the cell that links a first endogenous anchor transcription factor bound to the promoter of the target gene with a second endogenous transcription regulator (e.g., a transcription factor or transcription repressor), wherein the CIP-mediated linkage between the anchor transcription factor and the transcription regulator regulates the transcription of the target gene within the cell without the need for gene modification. Compositions used in practicing the method of the present invention are also provided. [Brief explanation of the drawing]
[0007] [Figure 1] This provides a general overview of TF-CIP-mediated regulation of transcription. An anchor transcription factor-binding ligand A binds to ligand B via chemically induced proximity, activating or repressing the transcription of a target gene or multiple genes, thereby recruiting or hijacking a second transcription factor that produces a therapeutic effect. [Figure 2] A general chemical structure of an embodiment of TF-CIP is shown. As illustrated, TF-CIP according to the embodiment includes a portion that binds one transcription factor linked by a chemical linker to a second portion that binds to an anchor transcription factor providing genomic localization. This structure includes linkers of different lengths and compositions. As illustrated, TF-CIP may also be configured as a “molecular adhesive,” where portions A and B are incorporated into a molecular adhesive that uses interactions between two proteins to facilitate the interaction. [Figure 3] This paper provides a description of the rationally designed construction of TF-CIP. Figure 3 shows the design of TF-CIP that hijacks BCL6 to kill ER-positive breast cancer cells or AR-positive prostate cancer cells. BCL6 is a transcription factor and oncogene that prevents the death of various cancer cells, including breast cancer cells, by binding to the epigenetic repressors BCOR, NCOR, and SMRT (PMID 18280243, 15531890, 10898795). Several inhibitors of the repressive function of BCL6 have been produced by other groups that prevent the binding of BCOR, NCOR, and SMRT to sites formed by the dimer surface of BCL6 (PMID 15531890), but these inhibitors have not been sufficiently active for therapeutic use (PMID 30335946). Chemical binding of BCL6 inhibitors such as BI3812 (PMID33208943) to estrogen compounds that bind to and induce proximity to cell death (apoptosis-promoting) promoters such as TP53, PUMA, and BIM converts cell death inhibitors into potent activators of cell death. [Figure 4] For example, Figure 3 provides the chemical structures of TF-CIP and its components, designed to hijack the inhibitory activity of BCL6 and convert it into an activator of cell death. Except for compounds 1 and 4, which are linker controls, each structure shown in Figure 4 includes an estrogen receptor binding moiety linked to a BCL6 inhibitor by a chemical linker, based on the aforementioned molecule BI3812 (PMID33208943). Structures using a similar strategy with an androgen analog linked to a BCL6 inhibitor, also based on the aforementioned molecule BI3812 (PMID33208943), are also shown. Structures containing a BCL6 inhibitor and a linker to control the linker effect are also shown. [Figure 5A]This paper describes the development of reporters for cell death or activation of pro-apoptotic pathways by deinhibited BCL6 protein or the pro-apoptotic protein FOXO3A. Figure 5A: The BCL6 reporter consists of an array of BCL6 binding sites isolated from different pro-apoptotic genes, including TP53, PUMA, and BIM. These genes have the ability to kill cells when simply overexpressed (PMID: 11463391). The actual human BCL6 binding site contains 10 base pairs on both sides, which takes advantage of the fact that transcriptional specificity is due to the coordinated binding of proteins within the enhancerosome (PMID: 9510247, 18206362). Therefore, the reporter system is multiplicative and useful for defining apoptotic responses in many different cell types. The FOXO3A reporter consists of an array of FOXO3A binding sites isolated from different pro-apoptotic genes, including TP53, PUMA, and BIM. These genes have the ability to kill cells when simply overexpressed. The actual human FOXO3A binding site contains 10 base pairs on both sides, which leverages the fact that transcriptional specificity is due to the coordinated binding of proteins within the enhancerosome (PMID9510247, 18206362). Therefore, the reporter system is multiplexed and useful for defining apoptotic responses in many different cell types. [Figure 5B] Provides a reporter DNA sequence for deinhibited BCL6. [Figure 5C] This provides a reporter DNA sequence for activating FOXO3A. [Figure 6]ER-TF-CIP activates the BCL6 reporter by derepressing BCL6, acting to induce cell death more effectively than BI3812. Panel A: Addition of ER-TF-CIP2 activates GFP expression by the BCL6 reporter at approximately 1 micromolar, which is potenter than BI3812. Note that higher concentrations saturate both binding sites (PMID:8752278, PMID:21406691), in this case the BCL6 protein and estrogen receptor, resulting in reduced reporter activation consistent with the "hook effect" properties of the bifunctional molecule. Panel B: ER-TFCIP6 induces cell death in ER-positive cells with amplified BCL6 (Karpas 442) more effectively than BI3812. Panel C: ER-TFCIP6 induces cell death in HEC293 cells. Panels D and E demonstrate that ER-TF-CIP6 did not kill two different ER-negative breast cancer cell lines, and therefore cell death depends on high levels of estrogen receptor expression, as occurs in breast cancer. Cell viability was measured using the PrestoBlue HS (resazurin) assay (1:10 ratio in medium and 1 hour incubation). [Figure 7A] This provides a step-by-step diagram of a method for selecting a transcription factor pair for a specific target gene expressed in a particular cell type of interest. Figure 7A shows a general method for selecting a cell type-specific transcription factor pair that can be used to define and anchor transcription factors and activating transcription factors, each having selective expression in the tissue of interest. [Figure 7B-1] An anchor transcription factor for the treatment of breast cancer has been identified that binds to the promoter of a specific target gene. [Figure 7B-2] Refer to the explanation in Figure 7B-1. [Figure 7C] This provides an example of how the combined use of transcription factors can target the TF-CIP effect on specific tissues. [Figure 8]A protocol is provided for selecting ligands for use in TF-CIP for transcription factors, as exemplified by the protocols shown in Figures 7A-7C. Pocket selection within anchor TFs includes, for example, the use of a sitemap (PMID:19434839), but other programs may also be used. Docking and hit scoring for pockets are described in PMID:17034125 and PMID:15027866. Another method for ligand selection is DNA-coding library screening using the protein of interest (PMID28094476). Yet another method for ligand selection is screening a library of small molecules using fluorescence polarization or other direct methods that measure binding. [Figure 9] Screening of TFCIPs functioning as molecular adhesives using the reporter introduced in Figure 5A. “Molecular adhesives” (PMID 33417864) are distinguished from “bifunctional molecules” such as those shown in Figure 2 by the fact that the linker is replaced by a more direct bond between the two binding sites. Molecular adhesives such as FK506 often exhibit good pharmacological behavior. Most importantly, they can involve several proteins at once by facilitating interactions between target proteins, such as cancer-driving factors, and several proteins within highly biologically specific enhancerosomes (PMID: 9510247, 18206362) (PMID 33417864). The reporters used for screening are shown in Figures 6A and 6B. [Figure 10] This provides structures for ligands of FOXO3A that bind to the proximal pocket adjacent to DNA. A general method for discovering these ligands is shown in Figure 8. [Figure 11] To avoid interfering with DNA binding, we provide structures for ligands of FOXO3A that bind to the distal region of DNA on the "back" of the DNA-binding domain. A general method for discovering these ligands is shown in Figure 8. [Figure 12]Provide the structures of known ligands of HIF1a that can be used in the synthesis of TF-CIP to convert cancer drivers into the promoters of apoptosis-promoting genes involved in cell death. These ligands are described in PMID:19950993 PMCID:PMC2819816 DOI:10.1021 / ja9073062PMID:19129502 PMCID:PMC2626723 DOI:10.1073 / pnas.0808092106. [Figure 13] Provide the structures of ligands for ppar-gamma, which can bind to the promoters of apoptosis-promoting genes and be used to synthesize TF-CIP to convert cancer drivers into the promoters of apoptosis-promoting genes involved in cell death. These ligands are described in PMID:24272485 DOI:10.1158 / 0008-5472.CAN-13-1836PMID:11900961 DOI:10.1016 / s0739-7240(01)00117-5. [Figure 14] Provide examples of oncogenic fusion transcription factors resulting from the fusion of one chromosomal region with another, such as creating hybrid or fusion proteins containing the DNA-binding domain of a transcription factor and another domain or sequence from a translocation partner. From PMID:33634124. [Figure 15] Provide examples of FLI1 ligands that can be used to construct TF-CIP that recruits or induces proximity to the promoter of an apoptosis-promoting gene that activates genes and kills cancer cells with its own driver. [Figure 16] Provide examples of ERG1 ligands that can be used to construct TF-CIP that recruits or induces proximity to the promoter of an apoptosis-promoting gene that activates genes and kills cancer cells with its own driver. [Figure 17]We provide ligands for FEV, an ETS family transcription factor expressed only in neurons that produce serotonin in the dorsal raphe of the human brain and regulate the production of TPH2, the rate-limiting enzyme for serotonin synthesis. To produce TF-CIP, which increases serotonin production, these ligands are ligated to ligands for preferred transcription activators that are selectively expressed in the target neuronal population. The ligands were identified by the steps illustrated in Figure 8. Some of these ligands also bind to the ERG protein by surface plasmon resonance. [Figure 18] This provides an example of myc ligands that can be used to synthesize TF-CIP, which puts myc, an oncogenic driver, into the promoter state of a cell death gene, by using TF-CIP consisting of one of the myc ligands, a chemical linker, and a ligand for BCL6 or FOXO3A that binds to the promoter of an apoptosis-promoting gene. This activates these genes and kills cancer cells with their own drivers. [Figure 19] As shown in Figure 3, we provide examples of ligands for E2F transcription factors that can function as anchors for recruiting repressors or, in other embodiments, as means for recruiting activators to the promoters of cell death genes. [Figure 20]Construct a TF-CIP similar to that shown in FIG. 4, and by making the cancer driver factor the promoter status of a cell death gene or other gene in ER-positive breast cancer cells, provide examples of estrogen analogs that can be used to change or activate their expression in response to the tumor's driving mechanism and induce cell death. This is, in this particular example, the estrogen receptor. References regarding these estrogen analogs include: PMID: 12656587 DOI: 10.1021 / ja0293305 PMID: 15101754 DOI: 10.1021 / ol0497537 PMID: 2362442 DOI: 10.1016 / 0022-4731(90)90123-a PMID: 1780954 DOI: 10.1016 / 0039-128x(91)90070-c PMID: 3702438 DOI: 10.1016 / 0022-4731(86)90117-2 PMID: 12794859 DOI: 10.1002 / cbic.200200499 PMID: 2738897 DOI: 10.1021 / jm00127a040 PMID: 2064992 DOI: 10.1016 / 0960-0760(91)90090-r PMID: 12236347 DOI: 10.1021 / ac020088u. [Figure 21] Provide examples of agonist ligands that can be used to make the androgen receptor the promoter status of a cell death gene in prostate cancer with amplification and overexpression of the androgen receptor. The synthesis of these ligands and their properties are described in PMID: 30271980 PMCID: PMC6123676 DOI: 10.1038 / s42003-018-0105-8 PMID: 10077001 DOI: 10.1210 / mend.13.3.0255 PMID: 16159155 PMCID: PMC2096617 DOI: 10.1021 / cr020456u PMID: 24909511 PMCID: PMC4571323 DOI: 10.1038 / aps.2014.18. [Figure 22]This document provides examples of progesterone receptor ligands that can be used to put the progesterone receptor into a promoter state for cell death (apoptosis-promoting) genes. These are described in PMID:17013809 DOI:10.1002 / med.20083 PMID:26153859 PMCID:PMC4650274 DOI:10.1038 / nature14583. [Figure 23] This document provides examples of BAF53a ligands that, when incorporated into TF-CIP, can be used to specifically activate cell death genes in SCC. These ligands can also be used as part of TF-CIP to traverse developmental barriers by removing developmental repression from genes that define polycomb eviction and lineage. Methods for identifying other suitable ligands are shown in Figure 8. [Figure 24A] Examples of chemical linker components that may be used to synthesize TF-CIP. These components may be used to provide the spacing of anchor transcription factors and their presentation to a second transcription factor. The linker can be selected and constructed from these and other published components to provide solubility to the TF-CIP compound. [Figure 24B] Refer to the explanation in Figure 24A. [Figure 25] TF-CIP is used to restore the function of haploinsufficient genes by increasing the transcription of non-mutant copies of the gene. The activating transcription factor can be selected based on the availability of a suitable ligand. [Figure 26] Panel A. BAF250B levels in human neural progenitor cells are restored using the FIRE Cas9 system (PMID 28916764), and the transcription factor is returned to the promoter state of one unmutated allele of the haploinsufficient BAF250B (Arid1B) gene. Panel B. After the addition of CIP, transcription is increased to the level of wild-type neural progenitor cells. The twofold transcriptional rescue shown here should reverse disease symptoms. [Figure 27]A chemical synthesis scheme for producing TF-CIP for TPH2 activation and enhancement of serotonin production in cells of the dorsal raphe of the human brain. Each synthesis method begins with a ligand for FEV, e.g., shown in Figure 17, and then a chemical linker is conjugated together with a ligand for Brd4 to produce a bifunctional FEV-TF-CIP that can activate serotonin production in cells having mutations in the TPH2 gene or one of the genes that regulate TPH2. Other activating transcription factors can be selected by screening, as described for molecular adhesives in Figure 9. [Figure 28] See the explanation in Figure 27. [Figure 29] This document provides a diagram of TF-CIP, which activates the expression of serotonin (Panel A) and dopamine (Panel B) synthesis, according to one embodiment of the present invention. [Modes for carrying out the invention]
[0008] Detailed explanation A method is provided for regulating the transcription of a target gene within a cell (which may be in vitro or in vivo). Embodiments of the method utilize a transcription factor-proximity chemoinducer (TF-CIP) to regulate, for example, enhance or reduce the transcription of a target gene in a cell (as illustrated in Figure 1). Embodiments of the method involve providing a proximity chemoinducer (CIP) within a cell, which ligates a first endogenous anchor transcription factor bound to the promoter of the target gene to a second endogenous transcription regulator (e.g., a transcription factor or transcription repressor), thereby controlling the transcription of the target gene within the cell via CIP-mediated ligation between the anchor transcription factor and the transcription regulator. Compositions used in practicing the method of the present invention are also provided.
[0009] Before the present invention is described in more detail, it should be understood that the present invention is not limited to the specific embodiments described and is therefore, of course, subject to change. Furthermore, since the scope of the present invention is limited only by the appended claims, it should also be understood that the terms used herein are for the purpose of describing only specific embodiments and are not intended to limit them.
[0010] Where a range of values is provided, unless the context explicitly indicates otherwise, it is understood that each intermediate value between the upper and lower limits of that range, up to one-tenth of the lower limit unit, and any other described values or intermediates within the range described herein are included in the invention. The upper and lower limits of these smaller ranges may be individually included in smaller ranges and are likewise included in the invention, according to any specifically excluded limits in the described range. Where a described range includes one or both limits, ranges excluding either or both of those included limits are also likewise included in the invention.
[0011] In this specification, the term “approximately” is used to indicate a specific range of numbers. In this specification, the term “approximately” is used to provide literal support for the exact number it precedes, and for any number that is close to or approximates the number it precedes. When determining whether a number is close to or approximates a specifically enumerated number, that close or approximate unenumerated number may, in the context in which it is presented, provide a substantial equivalent of the specifically enumerated number.
[0012] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. Any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention, but representative and exemplary methods and materials are described below.
[0013] All publications and patents cited herein are incorporated herein by reference, and by being incorporated herein by reference, disclose and describe the relevant methods and / or materials from which those publications are cited, as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. Any citation of a publication relates to its disclosure prior to the filing date of this application and should not be construed as accepting that the present invention is not entitled to precede any prior invention to such publication. Furthermore, the publication dates provided may differ from the actual publication dates and may need to be individually verified.
[0014] When used herein and in the appended claims, the articles “a,” “an,” and “the” refer to multiple subjects unless otherwise explicitly indicated by the context. Furthermore, it should be noted that the claims may be drafted to exclude any optional elements. Therefore, this statement is intended to function as an antecedent for the use of exclusive terms such as “solely” and “only,” or for the use of “negative” limitation, in relation to the enumeration of claim elements.
[0015] As will be apparent to those skilled in the art upon reading this disclosure, each of the distinct embodiments described and illustrated herein has distinct components and features that can be readily separated from or combined with any of the features of several other embodiments without departing from the scope or spirit of the invention. Any enumerated method may be performed in the order of the enumerated events, or in any other logically possible order.
[0016] Apparatus and methods are described or will be described for grammatical fluidity with functional description, but claims should not necessarily be construed as being limited by constructing “means” or “step” limitations unless expressly formulated under Section 112 of the United States Patent Act, and should be granted the meaning of the definitions and the full scope of the equivalent provided by the claims under the statutory principle of equivalents, and should be explicitly understood that if the claims are expressly formulated under Section 112 of the United States Patent Act, a full statutory equivalent should be granted under Section 112 of the United States Patent Act.
[0017] Methods and proximity chemistry-inducing factors (CIPs) As summarized above, aspects of the present invention include methods for regulating the transcription of a target gene within a cell. This method can be considered an inducible method for regulating the transcription of a target gene. Because the method is inducible, the regulation of the transcription of the target gene is not constitutive, but rather occurs in response to an applied stimulus, e.g., the provision of a CIP, as described in more detail below. Since the method is an inducible method for regulating the transcription of a target gene, it is a method for altering the transcription of the target gene in some way, e.g., a method for enhancing the transcription of the target gene, or a method for reducing the transcription of the target gene. The magnitude of the transcriptional change (compared to a suitable control, e.g., to the same system but without CIP) may vary, and in some cases the magnitude of the change, e.g., enhancement or reduction, may be twofold or more, e.g., fivefold or more, e.g., tenfold or more.
[0018] As summarized above, aspects of the present invention include methods for regulating the transcription of a target gene. The term gene refers to a genomic region that encodes functional RNA, including non-coding RNA, microRNA, enhancer RNA, or RNA that can be translated into protein products. The term gene is used in the conventional sense to refer to a region or domain of a chromosome that includes regulatory sequences, such as enhancers / silencers, promoters, terminators, non-coding RNA, microRNA, etc., as well as coding sequences in the form of exons separated by introns.
[0019] The specific target gene that is the focus of a given method can vary. In some cases, the target gene is a gene whose expression is enhanced, such as apoptosis-promoting genes (e.g., PUMA(BBC3), BIM(BCL2L11), BID, BAX, BAK, BOK, BAD, HRK, BIK, BMF, and NOXA(PMAIP1)), or a gene whose activity is inhibited, such as the anti-apoptotic gene BCL6, a beneficial therapeutic gene (e.g., rate-limiting enzyme (TPH2, etc.), a haploinsufficiency gene (ARID1B, etc.)). In some cases, the target gene is an overexpression gene whose expression should be reduced, such as an oncogene (MYC, etc.), a trisomy gene (chromosome 21 gene, etc.), or an amplified gene.
[0020] The gene categories listed above are merely examples of the types of genes that may be target genes for the methods described in this subject.Additional examples of target genes include, but are not limited to, developmental genes (e.g., adhesion molecules, cyclin kinase inhibitors, cytokines / lymphokines and their receptors, growth / differentiation factors and their receptors, neurotransmitters and their receptors); and oncogenes (e.g., ABLI, BCLI, BCL2, BCL6, CBFA2, CBL, CSFIR, ERBA, ERBB, EBRB2, ETSI, ETS1, ETV6, FOR, FOS, FYN, HCR, HRAS, JUN, KRAS, LCK, LYN, MDM2, MLL, MYB, MYC, MYCLI, MY CN, NRAS, PIM1, PML, RET, SRC, TALI, TCL3, and YES); tumor suppressor genes (e.g., APC, BRCA1, BRCA2, MADH4, MCC, NF1, NF2, RB1, TP53, and WTI); enzymes (e.g., ACC synthase and oxidase, ACP desaturase and hydroxylase, ADP-glucose pyrophorase, ATPase, alcohol dehydrogenase, amylase, amyloglucosidase, catalase, cellulase, chalcone synthase, chitinase, cyclooxygenase, decarbol Xylase, dextrinase, DNA and RNA polymerase, galactosidase, glucanase, glucose oxidase, granule-bound starch synthase, GTPase, helicase, hemicellulase, integrase, inulinase, invertase, isomerase, kinase, lactase, upase, lipoxygenase, lyso / yme, nopalin synthase, octopine synthase, pectin esterase, peroxidase, phosphatase, phospholipase, phosphorylase, phytase, plant growth regulator synthase, polygalactase Examples include thulonase, proteinase and peptidase, planase, recombinase, reverse transcriptase, RUBISCO, topoisomerase, and xylanase; chemokines (e.g., CXCR4, CCR5), RNA components of telomerase, vascular endothelial growth factor (VEGF), VEGF receptor, tumor necrosis factor nuclear factor kappa B, transcription factors, cell adhesion molecules, insulin-like growth factor, transforming growth factor beta family members, cell surface receptors, RNA-binding proteins (e.g., micronuclear endothelial RNA, RNA transport factors), translation factors, and telomerase reverse transcriptase.
[0021] Figure 1 provides an example of a general embodiment of the invention in which TF-CIP is used to regulate the transcription of a therapeutic gene. As shown in Figure 1, TF-CIP(A-linker-B) comprises ligand A, which specifically binds to an anchor transcription factor, and ligand B, which specifically binds to a regulatory factor, such as an activator, that is recruited (i.e., hijacked or rewired) to regulate the transcription of a target gene. Binding of TF-CIP to both the regulatory and anchor transcription factors results in the production of a binding complex by two binding sites A and B linked by a chemical linker and activation of the transcription of the target therapeutic gene. Figure 1 also provides an example of a general embodiment of the invention in which TF-CIP is used to repress the transcription of a therapeutic gene. As shown in Figure 1, TF-CIP(A-linker-B) comprises ligand A, which specifically binds to an anchor transcription factor that controls the transcription of a target gene, and ligand B, which specifically binds to a transcription repressor. Binding of TF-CIP to both the transcription repressor and anchor transcription factors results in the production of a binding complex that represses the transcription of the target gene.
[0022] Proximity chemoinducible factors (CIPs) As outlined above, embodiments of the method utilize proximity chemoinducers (CIPs). A CIP is a compound that induces proximity between a first endogenous anchor transcription factor that binds to the promoter of a target gene and a second endogenous transcription regulator under intracellular conditions. Since the CIP of the present invention induces proximity between at least one endogenous transcription factor and another endogenous transcription regulator (e.g., a transcription factor or transcription repressor), the CIP of the present invention may be referred to as a transcription factor-proximity chemoinducer (TF-CIP), as commonly shown in Figures 2 and 3. "Inducing proximity" means that the first and second endogenous factors spatially associate with each other through a binding event mediated by the CIP compound (PMID: 29590011), and the CIP compound is configured to bind to both endogenous factors simultaneously, thereby the CIP compound may be considered a bifunctional compound or molecular adhesive (PMID: 33417864). Spatial association is characterized by the presence of a binding complex containing CIP, a first endogenous anchoring transcription factor, and a second endogenous transcription regulator (e.g., transcription factors, transcription repressors, chromatin regulators, epigenetic regulators, and / or cancer-driving factors). In this binding complex, each member or component of the complex is bound to at least one other member of the complex. In this binding complex, the binding between various components can vary. For example, CIP may simultaneously bind to the domains of the first and second endogenous factors, thereby generating the binding complex and the desired spatial association, which ultimately leads to the desired transcriptional regulation of the target gene. This binding complex can be referred to as a triplicate complex consisting of three distinct non-covalent components: an endogenous anchoring transcription factor, an endogenous transcription regulator, and TF-CIP.
[0023] Any convenient compound that functions as a CIP can be used. A wide variety of compounds, including both natural and synthetic substances, can be used as CIPs. Applicable and readily observable or measurable criteria for selecting a CIP include: (A) the ligand is physiologically acceptable (i.e., does not have excessive toxicity to the cells or animals in which it is used), (B) it has a reasonable therapeutic dose range, (C) it can cross cell membranes and other membranes as needed, and (D) it binds to the target domains of endogenous anchored transcription factors and endogenous transcription regulators. A desirable criterion is that the compound is relatively physiologically inactive but is so for its CIP activity. In some cases, the ligand is non-peptide and non-nucleic acid. For some applications, compounds that can be taken orally (e.g., compounds that are stable in the gastrointestinal system and can be absorbed into the vascular system) are of interest.
[0024] The target CIP compound is small molecule and non-toxic. Small molecule means a molecule having a molecular weight of 5000 g / mol (Dalton) or less, for example, 2500 g / mol (Dalton) or less, for example, 1000 g / mol (Dalton) or less, for example, 500 g / mol (Dalton) or less. In some cases, the CIP used in the embodiments of the present invention has a molecular weight in the range of 250 to 1500 g / mol, for example, 300 to 1200 g / mol. Non-toxic means that the inducing factor, if present, does not exhibit substantially toxicity at concentrations of 1 g or more / kg body weight, for example, 2.5 g or more / kg body weight, for example, 5 g or more / kg body weight.
[0025] The CIP compounds used in embodiments of the present invention include a first ligand that specifically binds to an anchor transcription factor and a second ligand that is covalently bound to the second ligand that specifically binds to a transcription regulator. In other words, the CIP compound includes a linker component that can be a binding or linking moiety that links a first ligand that covalently binds to an anchor transcription factor and a second ligand that specifically binds to a transcription regulator. Terms such as "specific binding" and "specifically binds" refer to the ability of the first and second ligands to preferentially and directly bind to the corresponding anchor and transcription regulators compared to other molecules or moieties within the cell. In certain embodiments, the affinity between a given ligand and its corresponding factor when specifically bound to each other within the binding complex is 10 -5 M or less, 10 -6 M or less, 10 -7 M or less, 10 -8 M or less, 10 -9 M or less, 10 -10 M or less, 10 -11 M or less, 10 -12 M or less, 10 -13 M or less, 10 -14 M or less, or 10 -15 M or less and is characterized by a KD (dissociation constant) (note that in certain embodiments these values may be applicable to other specific binding pair interactions referred to elsewhere in this specification).
[0026] The nature of the first and second ligands of the CIP compound, as well as the linker component, can vary. In a given CIP compound, the first and second ligands are selected based on the nature of their corresponding anchor and transcription regulators, and examples of these and their corresponding ligands are provided below. Specificity of activity for a particular cell type can be provided by the selection of the first and second ligands of the CIP, which can be configured to recruit the anchor transcription factor and the transcription regulator in a manner that provides the desired cell or condition specificity. For example, the CIP can be engineered to induce proximity of the anchor transcription factor and the transcription regulator that are primarily present in the target cell of interest so that the CIP exhibits highly selective activity for that cell. The selectivity of a given CIP can be explained by the following formula. (Selectivity of anchor transcription factor expression) x (Selectivity of transcription regulator expression) x (Genome specificity of anchor transcription factor) = Selectivity of inductive activity
[0027] Generation of TF-CIP by rational design using existing components Figure 3 shows a rational design for constructing TF-CIP using existing components. As shown in Figure 3, a TF-CIP design configured to hijack BCL6 to kill ER-positive breast cancer cells or AR-positive prostate cancer cells. BCL6 is a transcription factor and oncogene that prevents the death of various cancer cells, including breast cancer cells, by binding the epigenetic repressors BCOR, NCOR, and SMRT (PMID:30335946) to the promoters of cell death genes. Several inhibitors of the repressive function of BCL6 have been produced to prevent BCOR, NCOR, and SMRT from binding to the site formed by the dimer surface of BCL6 (PMID:18280243), but these inhibitors have not been sufficiently active for therapeutic use (PMID:30335946).
[0028] Chemical binding of BCL6 inhibitors such as BI3812 (PMID32275432) to estrogen compounds that bind to and induce proximity of cell death (apoptosis-promoting) promoters such as TP53, PUMA, and BIM converts the cell death inhibitor into a cell death activator in cells with high estrogen receptor concentrations, such as breast cancer cells. An example of TF-CIP synthesized by the above protocol and designed to hijack the inhibitory activity of BCL6 and convert it into a cell death activator is shown in Figure 4. Details of the compound synthesis are provided in Section H of Example 1 below. Each structure includes an estrogen receptor-binding moiety linked to a BCL6 inhibitor by a chemical linker, based on the previously described molecule BI3812 (PMID32275432). These types of molecules may find use in the treatment of ER-positive breast cancer.
[0029] Furthermore, based on the previously described molecule BI3812 (PMID32275432), an example of a structure employing a similar strategy using an androgen analog linked to a BCL6 inhibitor is also shown. Later types of molecules may find use in the treatment of prostate cancer in which the AR gene is amplified or overexpressed.
[0030] Figures 5A–5C provide examples of how to measure the effects of TF-CIP to enable chemical optimization of linkers and ligands. In the illustrated embodiments, the reporter includes an array of BCL6 binding sites extracted from different pro-apoptotic genes, including TP53, PUMA, BIM, etc. These genes have the ability to kill cells when simply overexpressed (PMID11463391). The actual human BCL6 binding site contains 10 base pairs on both sides, taking advantage of the fact that transcriptional specificity is due to the coordinated binding of proteins within the enhancerosome (PMID:9510247, PMID:33957125, PMID1179502). Thus, the reporter system is multiplexed and useful for defining and quantifying apoptotic responses in many different cell types. A second reporter, used to provide mechanistic information regarding the specificity and action of the first reporter and capable of quantitatively evaluating different groups of cell death processes, contains an array of FOXO3A binding sites extracted from different pro-apoptotic genes, including TP53, PUMA, and BIM. These genes have the ability to kill cells when simply overexpressed or when FOXO3A is overexpressed (PMID 11463391). The actual human FOXO3A binding site contains 10 base pairs on both sides, which takes advantage of the fact that transcriptional specificity is due to the coordinated binding of proteins within the enhancerosome (PMID: 9510247, PMID: 18206362). Therefore, this reporter system is multiplexed and useful for defining apoptotic responses in many different cell types.
[0031] Using these reporter systems and direct measurements of cancer cell death, TF-CIP molecules constructed by the rational design exemplified in Figure 4 were evaluated. The evaluation results, relative potency, and mechanism of action of TF-CIP are shown in Figure 6. As shown in Panel A, the addition of ER-TF-CIP6 activates GFP expression by the BCL reporter at an EC50 of approximately 1–10 micromoles. This is substantially lower than the concentration of the parent compound BI3812 required to generate the phenotype in published studies. Note that higher concentrations saturate both binding sites (PMID:8752278, PMID:21406691), in this case the BCL6 protein and estrogen receptor, resulting in reduced reporter activation consistent with the "hook effect" properties of the bifunctional molecule. Panel B shows that ER-TF-CIP6 more effectively induces cell death in cancer cells containing an activated rearranged BCL6 gene and mildly overexpressed estrogen receptor (in this case, Karpas 422) than BI3812. Panel C demonstrates that ER-TF-CIP6 induces cell death in HEK293 cells. Panels D and E show that breast cancer cell lines that do not express the estrogen receptor or express it at low levels are not killed by ER-TF-CIP6. These studies show that ER-TF-CIP6 and other TF-CIPs, shown in Figure 4, recruit the estrogen receptor to the disinhibited BCL6 and subsequently activate pro-apoptotic genes that lead to cell death. Cell viability was measured using the PrestoBlue HS (resazurin) assay (1:10 ratio in medium and 1 hour incubation).
[0032] The therapeutic efficacy of ER-TF-CIP can be improved by several means. Firstly, estrogen analogs can be selected from many published estrogen analogs, including those with higher affinity for the estrogen receptor than estrodiol (DOI:10.1002 / cbic.200200499;PMID:12794859;PMID:15300835;PMID:2064992 PMID;2362442;PMID:3702438). The latter would have certain advantages in treating women who are not postmenopausal and who have high levels of estrogen that can compete with ER-TFCIP. The therapeutic efficacy of ER-TFCIP can be improved by using different linkers, which are discussed and illustrated in more detail later in this application. Different linkers can either more effectively position the estrogen receptor relative to the BCL6 protein or impart superior pharmacological characteristics to ER-TF-CIP. The therapeutic efficacy of ER-TFCIP can be improved by the use of different BCL6 ligands, some of which are described in the following publications: (PMID:32275432;PMID:30335946;PMID:28930682;PMID:27482887).
[0033] Generation of TF-CIP through rational design using novel components The studies described in the above section teach methods for constructing and evaluating TF-CIPs made from existing components. When existing components or ligands for anchor and regulatory transcription factors are unavailable, the following methods may be used to detect and evaluate these novel ligands. Figure 7A provides a step-by-step diagram of a method for selecting a pair of transcription factors that are selectively expressed in the target tissue of interest. From this analysis, anchor transcription factors for a specific target gene of interest are identified using the step-by-step explanation in Figure 7B. This representative example shows anchor transcription factors for the treatment of breast cancer. Final selection considerations for anchor transcription factors include a clear indication of the specificity of expression in the target tissue, the demonstrated role in the biological process being enhanced or repressed, and the importance of the binding site to the transcription factor. The application of these key factors provides both activating or repressing transcription factors that are selectively expressed in the target tissue of interest, as well as one or more candidate anchor transcription factors that are similarly expressed in the target tissue of interest, which can then be used for ligand selection.
[0034] For anchor transcription factors, a protocol for selecting ligands to be used in TC-CIP is provided using the protocol illustrated in Figure 8. Pocket selection within the anchor TF includes, for example, the use of the sitemap PMID:19434839, but other programs may also be used. Docking and hit scoring to the pockets are described in PMID:17034125 and PMID:15027866. Another method for ligand selection is DNA-coding library screening using the protein of interest (PMID:28094476). Yet another method for ligand selection is screening a library of small molecules using fluorescence polarization or other direct methods for measuring binding. Yet another method for detecting ligands is the use of nanoBRET (PMID30972335).
[0035] An additional method for detecting entirely new TF-CIPs within a small molecule library involves the use of reporters, as shown in Figure 9. Figure 9 describes the screening of TF-CIPs acting as molecular adhesives using reporters introduced in Figures 5A–5C. “Molecular adhesives” are distinguished from “bifunctional molecules,” such as those seen in Figure 2, by the fact that the linker is replaced by a more direct bond between two binding sites. Molecular adhesives such as FK506 or rapamycin (PMID: 33436864) often exhibit good pharmacological behavior. Most importantly, several proteins can be involved simultaneously, as shown in Figure 9, by facilitating interactions between target proteins, such as cancer-driving factors, and several proteins within a highly biologically specific enhancerosome (PMID: 9510247). Reporters for use in detecting BCL6 inhibitors (upper panel) and FOXO3A activators (lower panel) are shown. Molecules that act as molecular adhesives can be selected from a large library of compounds thanks to their ability to activate GFP or mCherry expression in a given cell type, such as breast cancer cells, prostate cancer cells, or lymphoma cells.
[0036] TF-CIP generation: Additional design considerations In some cases, the first and second ligands of CIP are small molecules, each having a molecular weight in the range of 50 to 1000 daltons, for example, 400 to 800 daltons. The chemical structures of the first and second ligands can vary widely, and they may be selected to provide desired specific binding to a target anchor transcription or transcription regulator. The first and second ligands may be selected to have little, if any, effect on the activity of the endogenous factors to which they are configured to bind, such as the anchor transcription or transcription regulator.
[0037] Therefore, for a given target gene, anchor transcription factors and ligands that can be used in TF-CIP can be identified using any convenient protocol. In some cases, the protocols described in Figures 7A-7C can be used to identify the anchor transcription factor of the target gene of interest. Thus, once a suitable transcription factor is identified, ligands that can be used in TF-CIP can be identified using the protocol described in Figure 8.
[0038] As described above, the first and second ligands of CIP can be bound to each other by linkage or via a linking portion, i.e., a linker. Any convenient linker can be used to link the first and second ligands together, where applicable. The linker of choice is one that provides stable association of the first and second ligands so that they can specifically bind to their respective endogenous factors within the cell. Because the linker provides stable association of the first and second ligands, the first and second ligands do not dissociate from each other under cellular conditions, such as conditions on the cell surface or inside the cell. The linker may be provided for stable association of the first and second ligands using any convenient bond, such as covalent or non-covalent bonding, and in some cases, the linker component is covalently bonded to both the first and second ligands.
[0039] If the CIP includes a linker covalently bonded to the first and second ligands, any convenient protocol may be used to form a covalent bond between the linker and each of the ligands. The desired linking protocol may include, but is not limited to, other types of bond-forming reactions, such as addition, removal, substitution, pericyclic, photochemical, redox, radical, carbene intermediate, and metathesis reactions. In some embodiments, the linker employs reactive linking chemistry, and for example, the reactive linker pair (provided, e.g., by the ligand and the part on the linker) may be, but is not limited to, maleimide / thiol; thiol / thiol; pyridyldithiol / thiol; succinimidyl iodoacetate / thiol; N-succinimidyl ester (NHS ester), sulfodichlorophenol ester (SDP ester), or pentafluorophenyl ester (PFP ester) / amine; bissuccinimidyl ester / amine; imide ester / amine; hydrazine or amine / aldehyde, dialdehyde or benzaldehyde. This includes isocyanates / hydroxyls or amines; hydrocarbons / periodates / hydrazines or amines; diazilines / aryl azides; pyridyl dithiols / aryl azides; alkynes / azides; carboxycarbodiimides / amines; amines / sulfo-SMCC (sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate) / thiols and amines / BMPH (N-[β-maleimidopropionic acid]hydrazide.TFA) / thiols; azides / triarylphosphines; nitrones / cyclooctin; azides / tetrazine and formylbenzamide / hydrazino-nicotinamide. In certain embodiments, the linker includes a linker that uses cycloaddition reactions, such as [1+2]-cycloaddition, [2+2]-cycloaddition, [3+2]-cycloaddition, [2+4]-cycloaddition, [4+6]-cycloaddition, or cheleotropic reactions to produce a 1,3-dipolar cycloaddition (e.g., azide-alkyne Huisgen cycloaddition), a Diels-Alder reaction, a reverse electron-demand Diels-Alder cycloaddition, an ene reaction, or a [2+2] photocycloaddition reaction.In some embodiments, the linker may include an alkyl chain, an alkoxy chain, an alkenyl chain, or an alkynyl chain, the number of carbon atoms in the chain may vary in some cases from 2 to 25, for example from 5 to 20, and one or more carbon atoms may be replaced by NH or CH3-N as a reactive functional group for covalent bonding.
[0040] In some cases, the linker is selected from a group including the following, where n is the total number of carbon atoms or possible carbon-substituted atoms, subcounted by k, m, and / or p: a) Cn alkyl chains, including cases where one or more carbon atoms are replaced with NH or CH3-N, L b) Cn alkoxy chains, including cases where one or more carbon atoms are replaced with NH or CH3-N, L c) Cn alkenyl or alkenyl oxy chains, including cases where one or more carbon atoms are replaced with NH or CH3-N, L d) Cn alkynyl or alkynyl oxy chains, including cases where one or more carbon atoms are replaced with NH or CH3-N, L e)L 1 -Ar-L 2 or L 1 -Het-L 2 (In the formula, L1 and L 2 This refers to an alkenyl, alkynyl, alkynyloxy, alkenyloxy, alkoxy, or alkyl chain of 1 to 10 atoms, which are bonded, carbon, or optionally substituted nitrogen, for example, CH2N(H)CH2, CH2OCH2, C5H 10 It may also be OCH2, etc. (see Figure 4); Ar is an optionally substituted 6-membered aryl group; Het is a 4-6 membered heterocycloalkyl group, or a 9-10 membered spirocyclic bicyclic heterocycloalkyl group, or an optionally substituted 3-6 membered heteroaryl group.
[0041] The structures of linker molecules and non-exclusive selected examples are shown in Figures 24A and 24B. Specific linkers that may be used in embodiments of the present invention include, but are not limited to, those listed below. TIFF2023549132000002.tif106128
[0042] Endogenous anchor transcription factors As summarized above, the CIP used in embodiments of the present invention includes, for example, a first ligand that specifically binds to an endogenous anchor transcription factor that binds to the promoter of a target gene, as shown in Figures 1 and 2 and described above. The term “transcription factor” is used in the conventional sense to refer to a protein that controls the rate of transcription of genetic information from DNA to RNA products, such as messenger RNA and non-coding RNA, by binding to a specific DNA sequence, for example, through the interaction of a DNA-binding domain with a transcription factor binding site or response element. Transcription factors may also be called sequence-specific DNA-binding factors.
[0043] The anchor transcription factors of the present invention are transcription factors that bind to the transcription factor binding site or response element of a target gene in a cell and regulate, for example, enhance or repress its transcription. Since anchor transcription factors are endogenous, they originate from the cell and are not heterologous to the cell. Therefore, the anchor transcription factors in the cell in which the method of the present invention is performed are encoded by chromosomal genes, where the chromosomal genes are not heterologous to the cell; that is, the genes are not introduced into the cell's chromosome by a vector such as a viral vector, or are genetically modified in any case.
[0044] Endogenous anchor transcription factors can vary widely depending on the properties and type of regulation of the desired specific target gene, e.g., transcription enhancement or reduction. Examples of anchor transcription factors that may be used in embodiments of the present invention include, but are not limited to, common transcription factors involved in the formation of pre-initiation complexes such as TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH, as well as upstream transcription factors such as proteins that bind somewhere upstream of the initiation site to stimulate or repress transcription. The endogenous anchor transcription factors used in a given embodiment of the present invention may be any of those listed in Lambert et al., “The Human Transcription Factors,” Cell (February 8, 2018) 172:650-665 and its supplements, as well as any transcription factors listed at http: / / humantfs.ccbr.utoronto.ca / . Specific anchor transcription factors for which use in exemplary applications of the present invention is found will be discussed in more detail below.
[0045] Endogenous transcription regulators As summarized above, the CIP used in embodiments of the present invention includes a second ligand that specifically binds to an endogenous transcription factor, as shown in Figures 1 and 2, for example, and as generally described above. The endogenous transcription factor is a protein that is endogenous to the cell and not genetically modified in any other way, as described above with respect to endogenous anchor transcription factors. The endogenous transcription factor is a protein that, when present in a binding complex with CIP and the anchor transcription factor, regulates the transcription of a target gene in a desired manner, for example, by enhancing or reducing the transcription of the target gene. For example, transcription factors can be diverse, and examples include transcription factors, as described above, as well as transcription regulatory proteins that do not directly bind to DNA. Non-DNA-binding transcription regulatory proteins that may be used in embodiments of the present invention include, but are not limited to, heterochromatin formation mediators such as mediators for histone methylation or demethylation, DNA methylation or demethylation, nucleosome crosslinking, histone acetylation or deacetylation, histone phosphorylation or dephosphorylation, histone ubiquitination or deubiquitination, and contact between DNA and histones. Specific mediators of interest include, but are not limited to, HP1 proteins such as HP1α and cs HP1α, histone H3K9 methylase, histone H3K9 demethylase, histone H3K27 methylase, histone H3K27 demethylase, histone H3K4 methylase such as MLL, histone H3K4 demethylase, histone acetyltransferase, histone deacetyltransferase, and the like. In some cases, transcription factors that do not bind to DNA are transcription repressor proteins, such as heterochromatin protein 1 (HP1) repressor protein and KRAB repressor protein. Specific transcription factors for which use in exemplary applications of the present invention is found are discussed in more detail below. In other cases, the transcriptional regulator may be an ATP-dependent chromatin regulator such as BAF or mSWI / SNF, PBAF, INO80 or LSH1, or any subunit contained together with a complex thereof.In some cases, embodiments of the present invention may use the recruitment of one of approximately 30 ATP-dependent chromatin regulators encoded in the mammalian genome, similar to BRG1(SMARCA 4) or BRM(SMARCA2) or their subunits and associated proteins, to specifically modify the Polycomb repression complex or other chromatin features.
[0046] cell As summarized above, aspects of the method of the present invention include providing CIP in cells in which the transcription of a target gene is regulated. The cells to which the CIP compound is provided may vary depending on the specific application being performed. Examples of cells of interest include eukaryotic cells, such as animal cells, where specific types of animal cells include, but are not limited to, yeast, insects, helminths, or mammalian cells. Examples of mammalian cells that may be used include horse, cattle, sheep, dogs, cats, mice, non-human primates, and human cells. Among the various species, various types of cells that may be used include hematopoietic, nerve, glial, mesenchymal, skin, mucous membrane, stroma, muscle (including smooth muscle cells), spleen, reticular endothelium, epithelium, endothelium, liver, kidney, gastrointestinal tract, lung, fibroblasts, and other cell types. Hematopoietic cells of interest include any of the erythroid, lymphoid, or myelomonocytic lineages, as well as nucleated cells that may be involved in myoblasts and fibroblasts. Also of interest are hematopoietic, nerve, interstitial, muscle, liver, lung, gastrointestinal, and mesenchymal stem cells, such as ES cells, epi-ES cells, and induced pluripotent stem cells (iPS cells), as well as other stem and progenitor cells. As summarized above, the cells to which the CIP compound is provided contain at least endogenous anchoring transcription factors and endogenous transcription regulators. Therefore, the cells are naturally containing anchoring transcription factors and transcription regulators and have not been manipulated to contain these factors. The cells may be in vitro or in vivo, as desired. In some cases, the cells in which the transcription of the target gene is regulated are part of a multicellular organism.
[0047] Method Steps Aspects of the present invention include providing CIP into cells, for example, as described above, in a manner sufficient to induce proximity of anchor transcription factors and transcription regulators as described above. Any convenient protocol for providing CIP into cells may be used. The specific protocol used may vary, for example, depending on whether the target cells are in vitro or in vivo. In a particular case, CIP is provided into cells by bringing the cells into contact with the CIP. In the case of an in vitro protocol, contact between the CIP compound and the target cells can be achieved using any convenient protocol. For example, target cells may be maintained in a suitable culture medium, and the CIP compound may be introduced into the medium as specifically described in the drawings.
[0048] In the case of in vivo protocols, any convenient administration protocol may be used. Various protocols may be used depending on the binding affinity of the CIP compound, the desired response, the mode of administration, the half-life, and the number of cells present. Therefore, CIP can be incorporated into various formulations for therapeutic administration, such as pharmaceutically acceptable vehicles (hereinafter also referred to herein as pharmaceutically acceptable delivery vehicles or carriers). More specifically, the CIP of the present invention can be formulated into pharmaceutical compositions in combination with appropriate pharmaceutically acceptable carriers or diluents, and can be formulated into solid, semi-solid, liquid, or gaseous preparations such as tablets, capsules, powders, granules, ointments (e.g., skin creams), solutions, suppositories, injections, inhalants, and aerosols. Therefore, drug administration can be achieved by various methods, including oral, rectal, parenteral, intraperitoneal, intradermal, transdermal, and intratracheal administration. In pharmaceutical dosage forms, CIP can be administered alone, or in appropriate association and combination with other pharmaceutically active compounds. The following examples are illustrative and not limiting.
[0049] For oral preparations, the drug can be used alone or in combination with appropriate additives to prepare tablets, powders, granules, or capsules. These preparations may be made using conventional additives such as lactose, mannitol, corn starch, or potato starch, binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch, or gelatin, disintegrants such as corn starch, potato starch, or sodium carboxymethylcellulose, lubricants such as talc or magnesium stearate, and, if necessary, diluents, buffers, wetting agents, preservatives, and flavoring agents.
[0050] The drug can be formulated into an injectable preparation by dissolving, suspending, or emulsifying it in an aqueous or non-aqueous solvent such as vegetable or other similar oils, synthetic fatty acid glycerides, esters of higher fatty acids, or propylene glycol. Conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers, and preservatives may be used as needed.
[0051] The drug can be used in aerosol formulations administered by inhalation. The compounds of the present invention can be formulated in pressurized, acceptable propellants such as dichlorodifluoromethane, propane, or nitrogen.
[0052] Furthermore, by mixing the compound with various bases such as emulsifying agents or water-soluble bases, the drug can be made into a suppository. The compound of the present invention can be administered rectally via a suppository. The suppository may contain a vehicle such as cocoa butter, carbowax, and polyethylene glycol, which melts at body temperature but solidifies at room temperature.
[0053] Unit dosage forms for oral or rectal administration, such as syrups, elixirs, and suspensions, may be provided, and each dosage unit, e.g., one teaspoon, one tablespoon, a tablet, or a suppository, contains a predetermined amount of the composition containing one or more inhibitors. Similarly, unit dosage forms for injection or intravenous administration may contain the inhibitor in the composition as a solution in sterile water, saline solution, or another pharmaceutically acceptable carrier.
[0054] As used herein, the term “unit dosage form” refers to a physically distinct unit suitable as a unit dose for human and animal subjects, each unit containing a calculated predetermined amount of the compound of the present invention in a quantity sufficient to produce the desired effect in conjunction with a pharmaceutically acceptable diluent, carrier, or vehicle. The specifications of the novel unit dosage forms of the present invention depend on the specific compound used, the effect to be achieved, and the pharmacodynamics associated with each compound in the host.
[0055] Pharmacovigilantly acceptable excipients such as vehicles, adjuvants, carriers, or diluents are readily available to the public. Furthermore, pharmaceutically acceptable auxiliary substances such as pH adjusters and buffers, tonicity adjusters, stabilizers, and wetting agents are readily available to the public.
[0056] Those skilled in the art will readily understand that dose levels can vary depending on the properties of the specific compound, the delivery vehicle, etc. A preferred dosage of a given compound can be easily determined by those skilled in the art through various means.
[0057] In these embodiments in which an effective amount of the active agent is administered to a living subject, the amount or dosage is effective when administered over a suitable period, such as one week or more, two weeks or more, three weeks or more, four weeks or more, eight weeks or more, etc., to produce the desired therapeutic effect. For example, the effective dose is the dose that produces the desired therapeutic effect when administered over a suitable period, such as at least about one week, possibly about two weeks or more, and up to about three weeks, four weeks, eight weeks or more. In some cases, an effective amount or dosage of the active agent not only slows or stops the progression of the disease state but also induces a reversal of the state, i.e., causes improvement of one or more symptoms of the state. For example, in some cases, the effective dose is an amount that, when administered over a preferred period, usually at least about one week, and possibly about two weeks or more, up to about three, four, eight weeks or more, improving one or more symptoms in a subject suffering from a disease state, and the magnitude of the improvement (e.g., as measured using a preferred protocol with relevant controls) may vary, for example, 1.5 times, 2 times, 3 times, 4 times, 5 times, and in some cases 6 times, 7 times, 8 times, 9 times, or 10 times or more. In certain embodiments, the method includes removing CIP from cells at some point after providing CIP. Removal of CIP from cells can be achieved by replacing CIP using any convenient protocol, for example, by removing CIP from the culture medium in which the cells are present, by stopping the administration of CIP to an animal containing the cells, by contacting the cells with a CIP-inducing proximity inhibitor, and by contacting the cells with a molecule that binds to only one of endogenous anchored transcription or transcription regulators. One specific type of inhibitor of TF-CP action would be a one-sided molecule consisting of a ligand for either an anchored or hijacked transcription factor, lacking the linker or other parts.
[0058] As summarized above, aspects of the present invention further include methods for inductively regulating the transcription of a target gene. Such methods include, for example, providing a proximity chemoinducer (CIP) to a cell (e.g., a eukaryotic cell) containing an endogenous anchor transcription factor and an endogenous transcription regulator under conditions sufficient to regulate the transcription of the target gene as described above. The CIP and the cell may be as described above. The transcription regulation can vary. In some cases, the regulation includes enhancing the transcription of a gene, for example, increasing the expression of an apoptosis-promoting gene whose death is desired by enhancing the desired activity within the cell, if the gene is beneficial in relation to a disease condition, for example, by enhancing the desired activity within the cell, or increasing the expression of a therapeutically beneficial gene, if an increase in the amount of the product of such a gene is beneficial in relation to a given disease condition. In such cases, the magnitude of the enhancement can vary, examples including substantially zero to some expression, and in some cases the magnitude can be more than 2 times, for example more than 5 times, for example more than 10 times. In some cases, regulation involves reducing the transcription of the target gene, for example, if the gene is harmful, such as a c-myc or triplet extension gene, such as Huntington. In such cases, the magnitude of the reduction can vary, ranging from some expression to virtually zero expression, and in some cases the magnitude of the reduction can be more than twofold, for example, more than fivefold, or for example, more than tenfold.
[0059] In some cases, the cells are cells of an object suffering from a diseased condition, i.e., cells obtained from such an object or cells that are part of such an object. The diseased conditions that the object may suffer from can be diverse, and examples of such diseased conditions include, but are not limited to, neoplastic disease conditions such as cancer, neurological conditions, immune disorders, gastrointestinal diseases, and cardiovascular diseases.
[0060] The subject method has been found to be useful in the treatment of a variety of different conditions where the regulation of target gene transcription in the host is desired. Treatment means that at least improvement of one or more of the symptoms associated with the condition that afflicts the host is achieved, and improvement is used broadly to refer to at least a reduction in a parameter associated with the condition being treated, such as the severity of the symptoms. Thus, treatment also includes situations in which a pathological condition, or at least its associated symptoms, are completely inhibited, for example, prevented from occurring, or stopped, for example, terminated, so that the host no longer suffers from that condition, or at least the symptoms that characterize that condition.
[0061] If the method is a method for treating a subject with respect to a condition, the method may further include, for example, assessing whether the subject has a given condition in order to confirm that a given CIP is suitable for use in treating the subject with respect to a condition. Any convenient diagnostic protocol appropriate for a given condition may be employed, and the selection of such a protocol will necessarily depend on the specific condition being treated.
[0062] Various subjects can be treated according to the subject's methods. In some cases, the subject is a “mammal” or “mammalian,” terms widely used to describe organisms belonging to the mammalian class, including carnivores (e.g., dogs and cats), rodents (e.g., mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees, and monkeys). In some cases, the subject is a human.
[0063] The following sections provide further details relating to exemplary embodiments of the method of the present invention.
[0064] Enhancement of transcription of apoptosis-promoting genes Embodiments of the present invention include, for example, a method for enhancing the transcription of pro-apoptotic genes in cells, as shown in Figure 3. Enhancing the transcription of pro-apoptotic genes means increasing the transcription of these genes. The magnitude of the transcriptional increase can vary. If the transcription of pro-apoptotic genes is undetectable by a suitable assay, embodiments of the method bring about a transcriptional enhancement that makes the transcription detectable, for example, by detecting the expression product or activity of the pro-apoptotic gene, such as apoptosis or its indicators. Given the existence of a detectable baseline level of transcription, the magnitude of the increase can vary, and in some examples, it may be 1.5 times or more, 2 times or more, for example, 5 times or more, for example, 10 times or more.
[0065] The method can result in the enhancement of transcription of various different pro-apoptotic genes. Pro-apoptotic genes are those whose expression products promote or induce apoptosis, i.e., programmed cell death that occurs in multicellular organisms, which can be characterized by various cellular changes such as bleeding, cell shrinkage, nuclear division, chromatin condensation, chromosomal DNA fragmentation, and overall mRNA breakdown and death. Specific pro-apoptotic genes of interest for transcription enhancement that can be achieved in embodiments of the present invention include, but are not limited to, PUMA(BBC3), BIM(BCL2L11), BID, BAX, BAK, BOK, BAD, HRK, BIK, BMF, and NOXA. Their relative ability to kill breast cancer cells when simply overexpressed is shown in Table 1. These measurements are useful for selecting transcription factors and ligands for targeting TF-CIP to specific effective pro-apoptotic genes such as BMF and HRK.
[0066] (Table 1) Useful examples of methods for selecting pro-apoptosis genes to hijack cancer-driving factors into endogenous cell death pathways. TIFF2023549132000003.tif88169* The values shown on the right are actual experimental values observed after induction of MCF7 ER-positive breast cancer (see the Experiment section).
[0067] Pro-apoptosis genes are particularly interesting because they are expressed at levels that balance anti-apoptotic genes, and this balanced steady state allows cells to survive.
[0068] The methods of these embodiments include, for example, providing in a cell a proximity chemoinducible factor (CIP) that links a first endogenous anchor transcription factor and a second endogenous oncogenic transcription factor that bind to the promoter of an apoptosis-promoting gene, by a protocol such as the one described above, wherein the CIP-mediated linking of the anchor transcription factor and the oncogenic transcription factor enhances the transcription of the apoptosis-promoting gene in the cell. In some cases, the CIP used in these embodiments is generally as described above and comprises a first ligand that specifically binds to the anchor transcription factor and a second ligand that specifically binds to the oncogenic transcription factor, wherein these first and second ligands are linked by a linker suitable for binding, for example, as described above.
[0069] In these embodiments, various different anchor transcription factors may be used. Figure 7 provides a systematic method for defining anchor transcription factors that are generalizable to any target gene and can be used to identify a transcription factor of interest that targets a given pro-apoptosis gene. As shown in Figure 7, the protocol begins by defining regions within the target gene that are available (i.e., accessible) for TF binding using existing resources such as ATAC- or DNAse-seq. The identified accessible regions are then evaluated for transcription factors rich in the target cell type, for example, by using Human Protein Altas (https: / / www.proteinatlas.org) or a similar resource, which provides specificity for TF-CIP function and therapeutic specificity. The lower panel of Figure 7 shows transcription factors that are enriched in breast cancer cells and bind to accessible regions of cell death (apoptosis-promoting) genes. Target anchor transcription factors include, but are not limited to, BCL6, TFAP2A, TFAP2C, SP3, TFDP1, ELK3, SREBF1, SREBF2, THRA, SMAD2, TFDP1, TCF3, USF1, USF2, VEZF1, PBX1, HIF1A, RARA, FOXO3A, MAZ, E2F1, E2F2, PAX9, STAT1, SPDEF, CREB3L1, BATF, XBP1, SIX4, AR, LEF1, MYB, RUNX1, and PPARG.
[0070] In the TF-CIP of these embodiments, any suitable ligand for these anchor transcription factors may be used, and suitable ligands include small molecule ligands that can specifically bind to the target anchor transcription factor without any associated negative effect on the ability of the anchor transcription factor to bind to the target DNA binding site. The molecular weight of these ligands may vary in some cases from 50 to 1200 daltons, for example from 200 to 500 daltons. A general method for identifying suitable ligands for use in such TF-CIP is provided in Figure 8. Suitable ligands for anchor transcription factors can be selected using any suitable protocol, such as an in silico screening protocol, as described below. For example, if the anchor transcription factor is FOXO3A, suitable ligands include, but are not limited to, those shown in Figures 10 and 11, with ligands for FOXO3A that bind to a site near the DNA shown in Figure 10 and ligands that bind to a site distal to the DNA shown in Figure 11. If the anchor transcription factor is HIF1A, suitable ligands include, but are not limited to, those shown in Figure 12. When the anchor transcription factor is ppar-gamma (PPARG), suitable ligands include, but are not limited to, those shown in Figure 13. When the anchor transcription factor is from the E2F family, examples of suitable ligands are shown in Figure 19, which can function as an anchor for recruiting repressors, for example, as shown in Figure 3, or, in other embodiments, as a means for recruiting activators to the promoter of a cell death gene.
[0071] In addition to anchor transcription factor ligands, the CIPs used in these embodiments also include ligands for oncogenic transcription factors. This embodiment is particularly important in the treatment of cancer, where TF-CIP induces cancer cells to commit suicide with their own driving factors. Oncogenic transcription factors are transcription factors whose activity contributes to a neoplastic, e.g., cancerous disease state. Oncogenic transcription factors can vary depending on the specific nature of the disease state being treated, and examples of oncogenic transcription factors include, but are not limited to, hormone receptors (e.g., estrogen, androgen, and progesterone receptors), oncogenic gene drivers (e.g., MYC, MLL fusion proteins, ETS fusion proteins, SS18-SSX fusion proteins), translocation fusion oncogenic genes, and proteins that regulate cell cycle entry (e.g., E2F family members). Figure 14 provides an example of oncogenic transcription factors that can be targeted by TF-CIP in embodiments of the present invention (PMID:33634124).
[0072] Ligands for exemplary cancer-driving or regulatory factors are shown in Figures 16–19 and include ligands for ERG fusion and Fli fusion oncogenes, FEV transcription activator, and Myc, which drive proliferation resulting from oncogenic mutations in many growth factor receptors and their associated signaling molecules.
[0073] In some cases, the oncogenic transcription factor is a hormone receptor. Hormone receptors that can be used as oncogenic transcription factors in embodiments of the present invention include, but are not limited to, estrogen receptors (ER), such as those provided in Figure 20; androgen receptors (AR), such as those provided in Figure 21; and progesterone receptors (PR), such as those provided in Figure 22. Examples of TFCIPs using ligands for estrogen and androgen receptors are shown in Figure 4, and their effects on cancer cells are shown in Figure 6. Any suitable ligand for these hormone receptors can be used, and preferred ligands include small molecule ligands that can specifically bind to the target hormone receptor without any associated negative effects on the hormone receptor's ability to enhance the transcription of the target pro-apoptosis gene, i.e., the transcriptional activity of the oncogenic transcription factor, when complexed with the anchor transcription factor by CIP. The molecular weight of these ligands can vary in some cases, in the range of 150 to 500 daltons, for example, 250 to 400 daltons. Suitable ligands for anchor transcription factors include BCL6 inhibitors such as BI3812. Other candidates include FOXO3A (Figures 11 and 12), which binds to and activates the expression of several pro-apoptotic genes in breast cancer and other cancers (PMID 15084260). Others may be selected using any convenient protocol, such as an in silico screening protocol, as detailed in Figure 8.
[0074] In some cases, the oncogenic transcription factor is BAF53a (also known as ACTL6a). BAF53a is a subunit of the BAF or mSWI / SNF chromatin regulatory complex (PMID:9845365) that counteracts Polycomb-mediated repression on the genome (PMID:27941796) and plays a crucial role in the activation of developmental repressor genes (PMID:20110991). In these cancers, BAF53a drives both initiation and proliferation and is expressed highly and specifically. In certain embodiments of the present invention, TF-CIP may be applied to squamous cell carcinoma (SCC). Therefore, killing SCC using overexpressed BAF53a is a specific treatment for SCC. Using a systematic approach defined in Figure 8, we identified BAF53a ligands illustrated in Figure 23. In the case of TF-CIP, these BAF53a ligands may be chemically bound to a suitable linker, for example, as described above. These ligands may either bind to the promoter of an apoptosis-promoting gene such as FOXO3A, or to a TF ligand that inhibits an anti-apoptotic gene, such as a BCL6 inhibitor. Since normal cells do not have BAF53a amplification, the resulting TF-CIP may be directed towards the specific death of SCCs rather than normal cells.
[0075] The first and second ligands of CIP used in the embodiments of the above method may be linked to each other by any convenient linker. As discussed above, the linker of interest is one that provides stable association of the first and second ligands so that the first and second ligands can specifically bind to their respective endogenous factors within the cell. Because the linker provides stable association of the first and second ligands to each other, the first and second ligands do not dissociate from each other under cellular conditions, such as conditions on the cell surface or inside the cell. The linker may be provided for stable association of the first and second ligands using any convenient bond, such as covalent or non-covalent bonding, and in some cases, the linker component is covalently bonded to both the first and second ligands. In some embodiments, the linker may be an alkyl chain, alkoxy chain, alkenyl chain, or alkynyl chain, and the number of carbon atoms in the chain may vary in some cases from 2 to 25, for example from 5 to 20, and one or more carbon atoms may be replaced with NH or CH3-N to provide covalent bonds to the first and second ligands. The linker may be bound to the first and second ligands at a position that does not adversely affect the ability of the ligands to bind to their respective endogenous factors. In some embodiments, there is no separate linker, and there is a linking component that is a molecule that induces proximity of the target transcription factor to an anchor transcription factor on the promoter of the target gene. An example of such a linking component is a molecular adhesive in which two different sides of a single molecule each bind to a separate transcription factor, as shown in Figure 2.
[0076] Methods for enhancing the transcription of apoptosis-promoting genes have been found to be useful, for example, in the treatment of oncogenic transcription factor-mediated neoplastic disease conditions, such as cancer. Cancers that can be treated using embodiments of the present invention include cancers mediated by oncogenic receptors (e.g., hormone receptors such as estrogen, progesterone, and androgen receptors), cancers mediated by oncogenic drivers (e.g., myc), cancers mediated by translocation fusion oncogenes (e.g., those shown in Figure 15), and cancers mediated by cell cycle entry transcription factors. Specific cancers that may be treated according to embodiments of the present invention include acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, AIDS-related cancers (e.g., Kaposi's sarcoma, lymphoma, etc.), anal cancer, appendiceal cancer, astrocytoma, atypical teratoma / rhabdoid tumor, basal cell carcinoma, cholangiocarcinoma (extrahepatic), bladder cancer, bone cancers (e.g., Ewing's sarcoma, osteosarcoma and malignant fibrous histiocytoma, etc.), brainstem glioma, brain tumors (e.g., (e.g., astrocytoma, central nervous system embryonic tumor, central nervous system germ cell tumor, craniopharyngioma, ependymoma, etc.), breast cancer (e.g., female breast cancer, male breast cancer, childhood breast cancer, etc.), bronchial tumors, Burkitt lymphoma, carcinoid tumors (e.g., childhood, gastrointestinal, etc.), primary cancer of unknown origin, cardiac tumors, central nervous system tumors (e.g., atypical teratoma / rhabdoid tumor, embryonic tumor, germ cell tumor, lymphoma, etc.), cervical cancer, childhood cancer, spinal cord tumor, chronic lymphocytic leukemia (CL) L), chronic myeloid leukemia (CML), chronic myeloproliferative neoplasms, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, ductal cancer (e.g., bile duct, extrahepatic, etc.), ductal carcinoma in situ (DCIS), embryonic tumors, endometrial cancer, ependymoma, esophageal cancer, sensory neuroblastoma, Ewing's sarcoma, extracranial germ cell tumors, extragonadal germ cell tumors, extrahepatic bile duct cancer, eye cancer (e.g., intraocular melanoma, retinoblastoma, etc.), fibrous histiocytoma of bone (e.g., malignant osteosarcoma, etc.) ), gallbladder cancer, stomach cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors (GIST), germ cell tumors (e.g., extracranial, extranasal, ovarian, testicular, etc.), gestational trophoblastic disease, glioma, pilocytic cell leukemia, head and neck cancer, heart cancer, hepatocellular carcinoma (liver) cancer, histiocytosis (e.g., Langerhans cell, etc.), Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, pancreatic islet cell tumors (e.g., pancreatic neuroendocrine tumors, etc.), Kaposi's sarcoma, kidney cancer (e.g., renal cell,Wilms' tumor, pediatric kidney tumors, etc.), Langerhans cell histiocytosis, laryngeal cancer, leukemia (e.g., acute lymphoblastic (ALL), acute myeloid (AML), chronic lymphocytic (CLL), chronic myeloid (CML), pilocytic cell leukemia, etc.), lip and oral cancer, liver cancer (primary), lobular carcinoma in situ (LCIS), lung cancer (e.g., non-small cell, small cell, etc.), lymphoma (e.g., AIDS-related, Burkitt, cutaneous T-cell, Hodgkin, non-Hodgkin, primary central nervous system (CNS), etc.), macroglobulinemia (e.g., Waldenström's disease), male breast cancer, bone and Malignant fibrous histiocytoma of osteosarcoma, melanoma, Merkel cell carcinoma, mesothelioma, subclinical primary metastatic squamous neck cancer, intermediate trunk cancer with NUT gene, oral cancer, multiple endocrine neoplasia syndrome, multiple myeloma / plasmacytic neoplasm, mycosis fungoides, myelodysplastic syndrome, myelodysplastic / myeloproliferative neoplasm, myeloid leukemia (e.g., chronic (CML), etc.), myeloid leukemia (e.g., acute (AML), etc.), myeloproliferative neoplasm (e.g., chronic, etc.), nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, oral cancer (e.g., lip, etc.), oropharynx Head cancer, osteosarcoma and malignant fibrous histiocytoma of bone, ovarian cancer (e.g., epithelial cell tumors, germ cell tumors, low-grade tumors, etc.), pancreatic cancer, pancreatic neuroendocrine tumors (islet cell tumors), papilloma, accessory ganglionoma, paranasal sinus cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pituitary tumor, pleuropulmonary blastoma, primary central nervous system (CNS) lymphoma, prostate cancer, rectal cancer, renal cell carcinoma, renal, pelvic and ureteral cancer, transitional cell carcinoma, retinoblastoma, rhabdomoma, salivary gland cancer, sarcoma (e.g., Ewing's, Kaposi's, bone marrow tumors, rhabdomyotum, soft tissue tumors, uterine tumors, etc.), Sezari Examples of treatable cancers include, but are not limited to, syndromes, skin cancers (e.g., childhood cancer, melanoma, Merkel cell carcinoma, non-melanoma, etc.), small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, squamous cell carcinoma of the neck (e.g., subclinical primary, metastatic, etc.), gastric cancer, T-cell lymphoma, testicular cancer, laryngeal cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell carcinoma of the kidneys, pelvis and ureters, urethral and kidney-pelvic cancer, urethral cancer, uterine cancer (e.g., endometrial cancer, etc.), uterine sarcoma, vaginal cancer, vulvar cancer, Waldenström macroglobulinemia, Wilms tumor, etc. Cancers that can be treated include epithelial cancers, e.g., carcinomas,For example, acinar carcinoma, acinar cell carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, adenosquamous cell carcinoma, adnexal carcinoma, adrenocortical carcinoma, alveolar carcinoma, melanocyte carcinoma, apocrine carcinoma, basal cell carcinoma, bronchoalveolar carcinoma, bronchial carcinoma, bronchial carcinoma, bile duct carcinoma, choriocarcinoma, pellucida carcinoma, glial carcinoma, cribriform carcinoma, ductal carcinoma, embryonic carcinoma, armory carcinoma, endometrioid carcinoma, epidermal carcinoma, mixed tumor-derived carcinoma, pleomorphic adenoma-derived carcinoma, follicular carcinoma of the thyroid, hepatocellular carcinoma, carcinoma in situ, carcinoma in the duct, Hurthle cell carcinoma, breast inflammation. Examples of cancers that fall under this category include, but are not limited to, uterine cancer, large cell carcinoma, invasive lobular carcinoma, lobular carcinoma, lobular carcinoma in situ (LCIS), medullary carcinoma, meningeal carcinoma, Merkel cell carcinoma, mucosal carcinoma, mucosal epidermal carcinoma, nasopharyngeal carcinoma, non-small cell carcinoma, non-small cell lung cancer (NSCLC), oat cell carcinoma, papillary carcinoma, renal cell carcinoma, dura mater carcinoma, sebaceous gland carcinoma, simple carcinoma, signet ring cell carcinoma, small cell carcinoma, small cell lung cancer, spindle cell carcinoma, squamous cell carcinoma, terminal ductal carcinoma, transitional cell carcinoma, tubular adenocarcinoma, and wart-like carcinoma.
[0077] Embodiments of the method may include assessing whether a subject with a neoplastic disease has a particular type of cancer. For example, if the subject has breast cancer, the method may include assessing whether the breast cancer is ER and / or PR positive, and then using an appropriate TFCIP to treat the particular cancer. For example, if the breast cancer is ER positive, a CIP having a ligand that binds to ERα may be used. Another example is prostate cancer driven by a gene that drives high levels of expression of an ETS fusion protein by a translocated ETS family member. Here, the ETS fusion protein may be hijacked by an ERG-binding ligand taken from a known ERG-binding molecule (e.g., shown in Figure 17) that is linked to a BCL6 inhibitor BI3812 or others (e.g., those mentioned above), similar to the strategies used to construct ER-TF-CIPS shown in Figures 3 and 4, which are selected, for example, as shown in Figure 8, or exhibit the reproductive activity shown in Figure 6. Another example is prostate cancer driven by an overexpressed androgen receptor or its regulatory region (PMID: 30033370). Here, as shown in Figure 4, the androgen-binding moiety can be chemically linked to an inhibitory ligand for the BCL6 anti-apoptotic protein. AR-TF-CIP induces proximity of activated AR to the BCL6 protein bound to the promoter of a gene that activates cell death (e.g., Table 1 above).
[0078] Reduction of the expression of overexpressed genes, such as oncogenes, trisomy genes, and amplified genes. Embodiments of the present invention include methods for reducing the transcription of specific genes whose overexpression contributes to pathological processes. Examples include, but are not limited to, pathogenic oncogenes resulting from the amplification of their DNA (e.g., BAF53a in squamous cell carcinoma), genes overexpressed as a result of trisomy (e.g., Down syndrome), genes overexpressed for various reasons leading to disease states (e.g., tumor necrosis factor in arthritis), and alleles containing triplet repeats. A general approach is shown in Figure 1 above. Reducing the transcription of a gene, such as an oncogene, means restricting or repressing, for example, inhibiting, the transcription of the gene, such as an oncogene. Embodiments of these methods include providing a proximity chemoinducible factor (CIP) in the cell that links a first endogenous anchor transcription factor and a second endogenous transcription regulator that bind to the promoter of a target gene, such as an oncogene, and the CIP-mediated linkage between the anchor transcription factor and the transcription regulator is performed in the cell. The transcription of genes, such as oncogenes, is reduced. The magnitude of the transcription reduction can vary. In some cases, the reduction can be more than twofold, for example, more than fivefold, for example, more than tenfold. In some cases, the CIP used in these embodiments is generally as described above and comprises a first ligand that specifically binds to an anchor transcription factor and a second ligand that specifically binds to a transcription regulator, and these first and second ligands are linked, for example, by binding or a suitable linker as described above. When the target gene is an oncogene, the target oncogene in such cases can vary. Examples of oncogenes whose transcription can be reduced include, but are not limited to, HER-2 / neu, RAS, MYC, SRC, hTERT, anti-apoptotic proteins, such as BCL-2, Ret, PI3 kinase, BRAF, EGFR, CTNNB1, etc.Additional oncogenes that may be targeted include, but are not limited to, those described in Bailey et al, “Comprehensive Characterization of Cancer Driver Genes and Mutations,” Cell. 2018 Aug 9;174(4):1034-1035. doi:10.1016 / j.cell.2018.07.034. The anchor transcription factors used in these embodiments bind to the transcription factor binding site or response element of the target oncogene. Therefore, the anchor transcription factor may vary depending on the target oncogene. Transcription factors that promote the expression of these oncogenes that may be used in embodiments of the present invention include, but are not limited to, those described in PMID:32728250, PMID:32728217, and PMID:32814038. Any suitable ligand for these anchor transcription factors may be used, and preferred ligands include small molecule ligands that can specifically bind to the target anchor transcription factor without any associated negative effect on the anchor transcription factor's ability to bind to the target DNA binding site. The molecular weights of these ligands can vary in some cases, ranging from 200 to 1200 daltons, for example, from 300 to 500 daltons. Suitable ligands for anchor transcription factors can be selected using any convenient protocol, such as small molecule binding screening or in silico screening protocols. Suitable ligands for use with E2F and Myc include, but are not limited to, those shown in Figures 18 and 19.
[0079] In addition to anchor transcription factor ligands, the CIPs used in these embodiments may also include ligands for transcription regulators that reduce the transcription of target genes within cells, such as oncogenes. The transcription regulators that reduce the transcription of oncogenes within cells when complexed with an anchor transcription factor via CIP can be diverse and may include transcription repressors. Examples of transcription repressors include, but are not limited to, heterochromatin protein 1 (HP1) repressor proteins, KRAB repressor proteins, H3K9 methyltransferases, and histone deacetylases. Any suitable ligand for these transcription regulators may be used, and preferred ligands include small molecule ligands that, when complexed with an anchor transcription factor via CIP, can specifically bind to the target transcription regulator without any associated negative impact on the factor's ability to reduce the transcription of the target oncogene. The molecular weight of these ligands may vary in some cases, ranging from 75 to 1000 daltons, for example, from 200 to 400 daltons. Examples of such ligands include both agonists and antagonists. Suitable ligands for anchor transcription factors can be selected using any convenient protocol, such as an in silico screening protocol, as described below.
[0080] The first and second ligands of CIP used in the embodiments of the above method may be linked to each other by any convenient linker component. As discussed above, the desired linker component, such as the one described above, provides stable association of the first and second ligands so that the first and second ligands can specifically bind to their respective endogenous factors within the cell. Because the linker component provides stable association of the first and second ligands to each other, the first and second ligands do not dissociate from each other under cellular conditions, such as conditions on the cell surface or inside the cell. The linker component may be provided for stable association of the first and second ligands using any convenient bond, such as covalent or non-covalent bonding, and in some cases, the linker component is covalently bonded to both the first and second ligands. In some embodiments, the linker may be an alkyl chain, alkoxy chain, alkenyl chain, or alkynyl chain, and the number of carbon atoms in the chain may vary in some cases from 2 to 25, for example from 5 to 20, with one or more carbon atoms replaced by NH or CH3-N. The linker may be bound to the first and second ligands at a position that does not adversely affect the ability of the ligands to bind to their respective endogenous factors. In other cases, the first and second ligands are contained within a single bifacial molecule or molecular adhesive. Examples of molecular adhesives include FK506, rapamycin, and cyclosporine A.
[0081] Methods for reducing oncogene transcription can be used, for example, in the treatment of oncogene-mediated neoplastic disease conditions, such as cancer, and examples of such cancers include, but are not limited to, those mentioned above.
[0082] Embodiments of the present invention also include reducing the transcription of allele-containing mutational elongation nucleotide repeats (NRs). For example, if the NR-containing gene is a single allele, embodiments of the method may include suppressing the expression of the single NR-containing allele by using an anchor transcription factor that binds to the NR-containing allele. In such embodiments, the target gene is a gene containing mutational elongation NRs, such as TNRs, where the mutational elongation nucleotide repeat domain is not present in the normal gene. A mutant elongation nucleotide repeat (NR) is a gene domain (i.e., region) containing multiple adjacent repeats of two or more nucleotide units, where the length of a given nucleotide repeat unit can vary in some cases between 2 and 10 nucleotides, for example between 3 and 6 nucleotides. Examples of repeat unit lengths include 2 nucleotides (e.g., when the mutant elongation nucleotide repeat is a dinucleotide repeat), 3 nucleotides (e.g., when the mutant elongation nucleotide repeat is a trinucleotide repeat), 4 nucleotides (e.g., when the mutant elongation nucleotide repeat is a tetranucleotide repeat), 5 nucleotides (e.g., when the mutant elongation nucleotide repeat is a pentanucleotide repeat), or 6 nucleotides (e.g., when the mutant elongation nucleotide repeat is a hexanucleotide repeat). Within a given domain, the domain may be homogeneous or heterogeneous with respect to the properties of the repeat units that constitute the domain. For example, a given domain may consist of a single type of repeat unit, i.e., the repeat units of the domain share the same (i.e., identical) nucleotide sequence, such that it is a homogeneous mutant NR domain. Alternatively, a given domain may consist of two or more different types of repeat units, i.e., repeat units with different sequences, so that it is a heterogeneous mutant NR domain. Mutant elongated nucleotide repeat domains can be located in the coding or non-coding regions of the target gene. In some cases, the elongated nucleotide repeat domain is located in the coding region of the target gene. In other cases, the elongated nucleotide repeat domain is located in the non-coding region of the target gene. The length and specific sequence of the mutant elongated nucleotide repeats can vary.
[0083] In some cases, a mutant elongated nucleotide repeat is a mutant elongated trinucleotide repeat. A mutant elongated trinucleotide repeat refers to a gene domain (i.e., region) containing multiple adjacent repeats of the same three nucleotides, and the length and specific sequence of mutant elongated trinucleotide repeats can vary, and mutant elongated trinucleotide repeat domains are not present in normal genes. Elongated trinucleotide repeat domains can be located in the coding or non-coding region of the target gene. In some cases, the elongated trinucleotide repeat domain is located in the coding region of the target gene. In some cases, the elongated trinucleotide repeat domain is located in the non-coding region of the target gene. In embodiments, the mutant repeat domain is located in the non-coding region of the target gene, such as the CTG extension located in the 3' untranslated region of the myotonic dystrophy-protein kinase gene, which leads to myotonic dystrophy (DM). In some cases, the mutant repeat domain is located within the coding region of the target gene, and therefore, in some cases, its presence within the target gene results in a corresponding domain or region (e.g., a poly-Q domain) in the product encoded by the gene. In some cases of this method, the mutation-extended TNR domain is a CTG repeat domain. In certain specific cases, the mutation-extended trinucleotide repeat domain contains 26 or more CTG repeats (e.g., 30 or more, 35 or more, etc.).
[0084] Mutant elongation trinucleotide repeats can vary in terms of nucleotide composition and length. Specific trinucleotides of interest include, but are not limited to, CAG, CTG, CGG, GCC, and GAA. In some cases, the mutant elongation trinucleotide repeat domain is a CAG repeat domain. The specific length of the repeat domain (e.g., a CAG repeat domain) can vary with respect to a specific target gene, insofar as it produces harmful activity, and in some cases, it may be 25 or more repeats, e.g., 26 or more repeats, 30 or more repeats, 35 or more repeats, 40 or more repeats, 50 or more repeats, or even 60 or more repeats. Specific target genes and expressed proteins of interest, associated diseases, and specific lengths of repeat sequences of the desired elongation CAG repeats include, but are not limited to, those provided in the table below.
[0085] TIFF2023549132000004.tif95147
[0086] The pathogenic repeat lengths shown are approximations and represent the most common range of pathogenic repeat lengths. The lower of the two numbers shown for each pathogenic repeat length indicates the length at which the pathogenic effect of the extension begins. Both cellular copies of an autosomal gene involved in NR disease may contain the NR domain, but generally, one copy of the target gene is mutated to have an extended NR segment, while the other copy (i.e., the allele) contains an unextended NR.
[0087] Enhancement of transcription of therapeutically beneficial genes Embodiments of the present invention include, for example, a method for enhancing the transcription of therapeutically beneficial genes within cells, as generally shown in Figure 1. Enhancing the transcription of therapeutically beneficial genes means increasing the transcription of therapeutically beneficial genes. The magnitude of the transcriptional increase can vary. If the transcription of therapeutically beneficial genes is undetectable by a suitable assay, embodiments of the method bring about a transcriptional enhancement such that the transcription becomes detectable, for example, by detecting the expression product or activity of the therapeutically beneficial gene, or by detecting improvement in one or more symptoms of a disease condition associated with a deficiency of the expression product of the therapeutically beneficial gene. Given the existence of a detectable baseline level of transcription, the magnitude of the increase can vary, and in some examples, it may be more than twofold, for example more than fivefold, or for example more than tenfold.
[0088] The method can result in enhancement of transcription of various different therapeutically beneficial genes, which may or may not be haploinsufficient genes. A therapeutically beneficial gene is one whose expression product is beneficial with respect to a given disease state. A therapeutically beneficial gene may be one in which an increase in the amount of its expression product results in improvement of one or more symptoms of a disease state associated with a low amount of its expression product, for example, a amount lower than that of a normal control. As illustrated in Figure 25, the treatment of a disease produced by the loss of a functional mutation in one allele of a dose-dependent gene can be treated with TF-CIP according to embodiments of the present invention, which may be specific to each dose-dependent gene. Examples of specific therapeutically beneficial genes whose transcription may be enhanced in embodiments of the present invention include, but are not limited to, genes encoding rate-limiting enzymes such as tryptophan hydroxylase (TPH2, for serotonin production), tyrosine hydroxylase (TH, for dopamine synthesis in Parkinson's disease), protein C, protein S, factor 8, and 5'-aminolevulinic acid synthase (ALA-S) in heme synthesis; and haploinsufficiency genes, such as ARID1B (BAF250b), TBR1, CHD8, BCL11a, and other haploinsufficiency genes. A corrected list of haploinsufficiency genes that may be targeted in embodiments of the present invention can be found in the Clinical Genome Resource https: / / search.clinicalgenome.org / kb / curations. Autism genes that may be targeted in embodiments of the present invention due to reduced expression and resulting in social dysfunction can be found in a corrected list from the Simons Foundation for Autism Research (https: / / gene.sfari.org / database / human-gene / ). Some of these genes have been shown to act on adult neurons in the dorsal raphe, suggesting that this disease may be treatable in adults as well (PMID:34239048;32568072).This is supported by published research showing that temporary reversals of autistic social characteristics may be brought about by small molecules that modulate serotonin effects but are too toxic for actual use in humans (PMID34239048).
[0089] The methods of these embodiments include, for example, providing in a cell a proximity chemoinducible factor (CIP) that links a first endogenous anchor transcription factor and a second endogenous transcription regulator, such as a transcription factor, which bind to the promoter of a therapeutically beneficial gene, by a protocol such as the one described above, and the CIP-mediated linking of the anchor and transcription regulator enhances the transcription of the therapeutically beneficial gene in the cell. In some cases, the CIP used in these embodiments is generally as described above and comprises a first ligand that specifically binds to the anchor transcription factor and a second ligand that specifically binds to the transcription regulator, and these first and second ligands are linked, for example, by binding or a preferred linker as described above.
[0090] In the methods of these embodiments, various different anchor transcription factors may be used, and the anchor transcription factor can be easily selected based on a specific therapeutically beneficial gene and its transcription factor. For example, if the beneficial therapeutic gene is TPH2, any of its transcription factors can be used as an anchor transcription factor. Examples of such transcription factors include, but are not limited to, FEV, EN1, GATA2, GATA3, LMX1B, POU3F2, INSM1, ESR2, CTCF, NR3C1, and REST. The selection of a pair of transcription factors selectively expressed in serotonergic cells of the dorsal raphe is shown in Figure 7A. For TPH2, the transcription factor that can be used is FEV, which binds to the promoter of the TPH2 gene (PMID: 10575032). Loss of FEV leads to a reduction in serotonin production (PMID: 12546819). The ligands for FEV were identified by virtual screening and biochemical analysis as shown in Figure 8, and are shown in Figure 17. These ligands can be linked to linkers, as well as ligands for other transcription factors selectively expressed in the dorsal raphe of the brain, as shown in Figures 24A and 24B, to result in cell-type-specific and circuit-selective expression of serotonin production. Since TPH2 is rate-limiting for serotonin synthesis, this would result in increased serotonin production for treating, for example, mood disorders, depression, autism, and other serotonin-related disorders (Figure 29, Panel A). A synthetic method for generating TF-CIP, which recruits the activator BRD4 to the promoter of the TPH2 gene by binding to FEV, is shown in Figures 27 and 28.
[0091] Using a parallel strategy, dopamine synthesis can be increased by stimulating the production of the rate-limiting enzyme tyrosine hydroxylase in the substantia nigra of early Parkinson's disease, where dopaminergic cells are not completely lost, as shown in Figure 29, Panel B. The rationale for increasing dopamine synthesis in substantia nigra dopaminergic neurons is that these neurons cease to produce dopamine in the early stages of Parkinson's disease (PD) (Heo et al., 2020 PMID:31928877). These “dormant” dopaminergic neurons are associated with PD symptoms prior to neuronal death. Importantly, Heo et al. found that increasing the activity of substantia nigra dopamine neurons in a rodent model of PD rescued dopamine production and motor control. Their results suggest that restoring dopamine production in the substantia nigra of early PD rescues motor function and thereby may serve as a therapeutic intervention for PD that does not currently exist. As shown in Figure 29, panel B, dopamine production can be enhanced using TF-CIP, which is designed to increase the transcription of tyrosine hydroxylase (TH), the rate-limiting enzyme for dopamine synthesis.
[0092] A common strategy for encoding cell specificity in TF-CIP is to target transcription factor pairs that are selectively co-expressed in the target cell type, as illustrated in Figures 7A and 7C. Using dopaminergic neurons from the substantia nigra as an example, we identified transcription factor pairs that were significantly co-expressed across single human dopaminergic neurons dissected from the substantia nigra (r>0.5 and p<0.05 or Pearson correlation at overlap analysis p<0.05) (Agarwal et al., 2020 https: / / doi.org / 10.1038 / s41467-020-17876-0). Subsequently, we investigated the expression of dopaminergic transcription factor pairs in single cells across all human tissues (Human Protein Atlas; Karlsson et al., 2021 DOI:10.1126 / sciadv.abh2169). By excluding transcription factor pairs that showed co-expression outside of dopaminergic neurons, we obtained 14 dopaminergic neuron-selective transcription factor pairs that could be used as targets for TF-CIP to treat PD. These pairs are: RORA:SOX6, RORA:AEBP2, AEBP:LCORL, PBX1:SETBP1, PBX1:PIAS1, PBX1:ZEB1, FOXP2:ZEB1, FOXP2:KLF12, MYT1L:ZNF91, ZFHX3:ZNF91, ZFHX3:ZNF420, ZNF91:ZNF420, AFF3:THRB, and TAX1BP1:TCF25.
[0093] In another example where the beneficial therapeutic gene is ARID1B, the anchor transcription factor can be selected using the systematic process described in Figure 7B. Examples of such transcription factors include, but are not limited to, TBR1, OTX2, GATA2, GATA3, FEV, ETS1, KLF5, LMX1B, and PAX5. TBR1 controls the expression of ARID1b, and TBR1 mutant mice have reduced ARID1B production (PMID:27325115 PMID:25356899 PMID:28584888). Ligands for these anchor transcription factors can be defined by the process illustrated in Figure 8. The molecular weight of these ligands can vary in some cases, ranging from 75 to 1000 daltons, for example, from 200 to 400 daltons. Suitable ligands for anchor transcription factors can be selected or discovered using any convenient protocol, such as an in silico screening protocol, as shown in Figure 8.
[0094] In addition to anchor transcription factor ligands, the CIPs used in these embodiments also include ligands for transcription regulators, which in some cases are, for example, a second endogenous transcription factor expressed in a tissue type that retains the target cell, such as the dorsal raphe (for enhancing TPH2 for serotonin production) or the human brain (for ARID1B). The transcription regulators may vary, for example, depending on the specific nature of the disease condition being treated and the cells in which transcriptional regulation is desired. For example, if the beneficial therapeutic gene to be targeted is TPH2, possible transcription regulators to be used include, but are not limited to, FEV, BRD4, P300 / CBP, PAX5, POU6F2, KLF5, SOX14, POU3F3, SATB2, nBAF, etc. In another example where the target beneficial therapeutic gene is ARID1B, possible transcription factors to be used include, but are not limited to, TBR1, selected to optimize cell type specificity using a quantitative proteome map of the human body (PMID32916130) and the procedures described in Figures 7B and 8.
[0095] Any suitable ligand for these transcription factors may be used, and suitable ligands include small molecule ligands that can specifically bind to the target transcription factor without any associated negative effects on the transcription of beneficial therapeutic genes targeted when complexed with the anchor transcription factor by CIP, i.e., the transcription factor's ability to enhance the transcriptional activity of the transcription factor. A systematic process for selecting ligands is shown in Figure 8. The molecular weight of these ligands may vary in some cases, ranging from 70 to 1100 daltons, for example, from 300 to 600 daltons. Examples of such ligands include both agonists and antagonists. The first and second ligands of CIP used in the embodiments of the above method may be linked to each other by any suitable linker as described above. As discussed above, the linker of interest is one that provides a stable association of the first and second ligands so that the first and second ligands can specifically bind to their respective endogenous factors within the cell. The linker provides stable association of the first and second ligands with each other, so that the first and second ligands do not dissociate from each other under cellular conditions, such as conditions on the cell surface or inside the cell. The linker may be provided for the stable association of the first and second ligands using any convenient bond, such as covalent or non-covalent bonds, and in some cases, the linker component is covalently bonded to both the first and second ligands. In some embodiments, the linker may be an alkyl chain, an alkoxy chain, an alkenyl chain, or an alkynyl chain, as shown, for example, in Figures 24A and 24B, and the number of carbon atoms in the chain may vary in some cases from 2 to 25, for example from 5 to 20, and one or more carbon atoms may be replaced by NH or CH3-N. The linker may be bound to the first and second ligands at a position that does not adversely affect the ability of the ligands to bind to their respective endogenous factors.
[0096] The methods of these embodiments are found to be used in the treatment of any disease condition in which an increase in the transcription of beneficial therapeutic genes is desired. Examples of such disease conditions include, but are not limited to, disease conditions characterized by modified brain serotonin and associated with the abnormal expression of rate-limiting enzymes such as TPH2, such as depression, anxiety, panic disorder, obsessive-compulsive disorder, attention deficit hyperactivity disorder, sleep and circadian rhythm disorders, irritable bowel syndrome, PMS / hormone dysfunction, fibromyalgia, obesity, alcoholism, aggression, hyperserotonemia, social disorder, autism spectrum disorder, and speech disorders (PMID, 30552318, 32883965, 22826343, 22698760, 14675805). In addition, ARID1B causes haploinsufficiency disorders such as intellectual disability and autism spectrum disorder; the CHD7 gene causes CHARGE syndrome; the RUNX2 gene causes cleidocranial dysostosis; ADAMTS2, COL1A1, COL1A2, COL3A1, COL5A1, COL5A2, PLOD1, FKBP14, TNXB, COL12A1, B4GALT7, B3GALT6, CHST14, DSE, C1R, C1S, SLC39A13, ZNF469, PRDM5 cause Ehlers-Danlos syndrome; TNFAIP3 causes A20 haploinsufficiency; FBN1 causes Marfan syndrome; SHANK3 causes 22q13 deletion syndrome; and SCN1A causes Dravet syndrome. A list of corrected genes that generate human diseases when the dosage is reduced by 50% and that can be treated by embodiments of the present invention is available from the Clinical Genome Resource (https: / / search.clinicalgenome.org / kb / curations).
[0097] Combination therapy Aspects of the present disclosure further include combination therapies. In certain embodiments, the method of the subject involves administering a therapeutically effective amount of one or more additional activators in combination with the CIP of the present invention. Combination therapy means that CIP can be used in combination with another therapeutic agent to treat a single disease or condition. Alternatively, a second TF-IP can be used to overcome drug-induced resistance to a first CIP or to enhance the apoptotic activity of a first CIP. This can be achieved by using a ligand to another anchor transcription factor that binds to one or more apoptotic gene promoters / enhancers. In some embodiments, the CIP compound of the present disclosure is administered concurrently with the administration of another therapeutic agent, which may be administered as an ingredient in a composition containing the compound of the present disclosure or as an ingredient in a different composition. In certain embodiments, a composition containing the compound of the present disclosure is administered before or after the administration of another therapeutic agent. The compound of the subject may be administered in combination with other therapeutic agents in a variety of therapeutic applications. The above-mentioned applications are examples of therapeutic applications intended for combination therapy.
[0098] As discussed above, in some cases CIPs are used to treat neoplastic conditions. Therefore, CIPs of such embodiments can be used in combination with any agent useful for treating neoplastic conditions, such as anticancer agents and antitumor agents. In such cases, agents of interest that can be used in combination with the subject CIS compound include, but are not limited to, cancer chemotherapeutic agents, agents that act to reduce cell proliferation, antimetabolites, microtubules that affect agents, hormone modulators and steroids, natural products and biological response modifiers, as will be described in more detail below.
[0099] Examples of cancer chemotherapeutic agents include non-peptide (i.e., non-proteinogenic) compounds that reduce the proliferation of cancer cells and encompass cytotoxic and cell-suppressant agents. Non-limiting examples of chemotherapeutic agents include alkylating agents, nitrosoureas, antimetabolites, antitumor antibiotics, plant (vinca) alkaloids, and steroid hormones. Peptide compounds may also be used. Preferred cancer chemotherapeutic agents include drastatin and its active analogs and derivatives, and auristatin and its active analogs and derivatives (e.g., monomethyl auristatin D (MMAD), monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), etc.). See, for example, WO96 / 33212, WO96 / 14856, and US6,323,315. For example, drastatin 10 or auristatin PE may be included in the antibody-drug conjugate of this disclosure. Furthermore, suitable cancer chemotherapeutic agents include mytansin and its active analogues and derivatives (see, for example, EP1391213 and Liu et al (1996) Proc. Natl. Acad. Sci. USA 93:8618-8623), duocalmycin and its active analogues and derivatives (including, for example, synthetic analogues KW-2189 and CB1-TM1), and benzodiazepines and their active analogues and derivatives (for example, pyrrolobenzodiazepine (PBD)). Agents that act to reduce cell proliferation are known and widely used in the art. Examples of such agents include, but are not limited to, alkylating agents such as nitrogen mustard, nitrosourea, ethyleneimine derivatives, alkyl sulfonates, and triazenes, as well as mechloretamine, cyclophosphamide (Cytoxan®), melphalan (L-sarcolicin), carmustine (BCNU), lomustine (CCNU), semustine (methyl-CCNU), streptozosin, chlorozotosin, uracil mustard, chlormethine, ifosfamide, chlorambucil, pipobromane, triethylenemelamine, triethylenethiophosphoramine, busulfan, dacarbazine, and temozomide.Examples of antimetabolites include, but are not limited to, folate analogs, pyrimidine analogs, purine analogs, and adenosine deaminase inhibitors, as well as cytarabine (CYTOSAR-U), cytosine arabinoside, fluorouracil (5-FU), phloxuridine (FudR), 6-thioguanine, 6-mercaptopurine (6-MP), pentostatin, 5-fluorouracil (5-FU), methotrexate, 10-propargyl-5,8-dideazafolate (PDDF, CB3717), 5,8-dideazatetrahydrofolate (DDATHF), leucovorin, fludarabine phosphate, pentostatin, and gemcitabine. Suitable natural products and their derivatives (e.g., vinca alkaloids, antitumor antibiotics, enzymes, lymphokines, and epipodophyllotoxins) include, but are not limited to, Ara-C, paclitaxel (Taxol®), docetaxel (Taxotere®), deoxycoformycin, mitomycin C, L-asparaginase, azathioprine; Brekiner; alkaloids, e.g., vincristine, vinblastine, vinorelbine, vindesine, etc.; podophyllotoxins, e.g., etoposide, teniposide, etc.; antibiotics, e.g., anthracyclines Examples include phosphorus, daunorubicin hydrochloride (daunomycin, rubidomycin, serubicin), idarubicin, doxorubicin, epirubicin, and morpholino derivatives; phenoxyzombine cyclopeptides, e.g., dactinomycin; basic glycopeptides, e.g., bleomycin; anthraquinone glycosides, e.g., plicamycin (mitramycin); anthracendiones, e.g., mitoxantrone; azilinopyrroindelegones, e.g., mitomycin; macrocyclic immunosuppressants, e.g., cyclosporine, FK-506 (tacrolimus, Prograf), rapamycin, etc. Other antiproliferative cytotoxic agents include navelben, CPT-11, anastrazole, letrazole, capecitabine, reloxafine, cyclophosphamide, ifosamide, and droloxafine.Microtubule-inhibiting agents with antiproliferative activity are also suitable for use, and are not limited to these, but include, allocolchicine (NSC406042), halichondrin B (NSC609395), colchicine (NSC757), colchicine derivatives (e.g., NSC33410), dorustatin 10 (NSC376128), mytansine (NSC153858), rhizoxin (NSC332598), paclitaxel (Taxol®), Taxol® derivatives, docetaxel (Taxotere®), thiocolchicine (NSC361792), tritylcisterine, vinblastine sulfate, vincristine sulfate, and natural and synthetic epotilones, and are not limited to, epotilone A, epotilone B, discodermorid; estramustine, nocodazole, etc. Suitable hormone regulators and steroids (including synthetic analogs) for use include, but are not limited to, adrenocorticosteroids such as prednisone and dexamethasone; estrogens and pregestins such as hydroxyprogesterone caproate, medroxyprogesterone acetate, megestrol acetate, estradiol, clomiphene, and tamoxifen; and adrenal cortical inhibitors such as aminoglutethimide and 17α-ethinylestradiol. Examples include diethylstilbestrol, testosterone, fluoxymesterone, dromostanolone propionate, testolactone, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianicene, hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesterone acetate, leuprolide, flutamide (drogenyl), toremifene (Fareston), and Zoladex®. Estrogen stimulates proliferation and differentiation. Therefore, compounds that bind to estrogen receptors are used to block this activity. Corticosteroids can inhibit T cell proliferation.Other suitable chemotherapeutic agents include metal complexes, e.g., cisplatin (cis-DDP), carboplatin; urea, e.g., hydroxyurea; and hydrazine, e.g., N-methylhydrazine; epidophyllotoxin; topoisomerase inhibitors; procarbazine; mitoxantrone; leucovorin; tegafur, etc. Other antiproliferative agents of interest include immunosuppressants, e.g., mycophenolic acid, thalidomide, desoxysperguarin, azasporin, leflunomide, mizoribine, azaspiran (SKF105685), Iressa® (ZD1839, 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-(4-morpholinyl)propoxy)quinazoline), etc. Taxanes are preferred for use. "Taxane" includes paclitaxel, as well as any active taxane derivatives or prodrugs. "Paclitaxel" (which should be understood herein to include analogues, formulations, and derivatives such as, for example, docetaxel, TAXOL®, TAXOTERE® (formulations of docetaxel), 10-desacetyl analogues of paclitaxel, and 3'N-desbenzoyl-3'Nt-butoxycarbonyl analogues of paclitaxel) can be readily prepared using techniques known to those skilled in the art (WO94 / 0 See also U.S. Patent Nos. 7882, WO94 / 07881, WO94 / 07880, WO94 / 07876, WO93 / 23555, WO93 / 10076; U.S. Patent Nos. 5,294,637; 5,283,253; 5,279,949; 5,274,137; 5,202,448; 5,200,534; 5,229,529; and EP590,267) or available from various commercial sources, including, for example, Sigma Chemical Co., St. Louis, Mo. (T7402 from Taxus brevifolia; or T-1912 from Taxus jananensis). Paclitaxel should be understood to refer not only to the commonly available chemical forms of paclitaxel, but also to its analogues and derivatives (e.g., Taxotere® docetaxel as mentioned above) and paclitaxel conjugates (e.g., paclitaxel-PEG, paclitaxel-dextran, or paclitaxel-xylose).The term "taxane" includes a variety of known derivatives, including both hydrophilic and hydrophobic derivatives. Taxane derivatives include, but are not limited to, galactose and mannose derivatives described in International Patent Application WO99 / 18113; piperazino and other derivatives described in WO99 / 14209; taxane derivatives described in WO99 / 09021, WO98 / 22451, and U.S. Patent No. 5,869,680; 6-thio derivatives described in WO98 / 28288; sulfenamide derivatives described in U.S. Patent No. 5,821,263; and taxol derivatives described in U.S. Patent No. 5,415,869. It further includes, but is not limited to, prodrugs of paclitaxel, including those described in WO98 / 58927, WO98 / 13059, and U.S. Patent No. 5,824,701. Suitable biological response modifiers for use include, but are not limited to, (1) inhibitors of tyrosine kinase (RTK) activity, (2) inhibitors of serine / threonine kinase activity, (3) tumor-associated antigen antagonists such as antibodies that specifically bind to tumor antigens, (4) apoptosis receptor agonists, (5) interleukin-2, (6) IFN-α, (7) IFN-γ, (8) colony-stimulating factors, and (9) inhibitors of angiogenesis.
[0100] In some cases, the CIP of the present invention is used in combination with an immunotherapy agent. Examples of immunotherapies include anti-PD-1 / PD-L1 immunotherapies such as anti-PD-1 / PD-L1 therapeutic antagonists, and examples of such antagonists include, but are not limited to, OPDIVO® (nivolumab), KEYTRUDA® (pembrolizumab), Tecentriq® (atezolizumab), durvalumab (MEDI4736), avelumab (MSB0010718C), BMS-936559 (MDX-1105), CA-170, BMS-202, BMS-8, BMS-37, and BMS-242. Nivolumab (OPDIVO®) is a humanized IgG4 anti-PD-1 monoclonal antibody used to treat cancer. Pembrolizumab (KEYTRUDA®), formerly known as MK-3475, lambrolizumab, etc., is a humanized antibody used in cancer immunotherapy targeting the PD-1 receptor. Atezolizumab (Tecentriq®) is a fully humanized, engineered monoclonal antibody of the IgG1 isotype against the PD-L1 protein. Durvalumab (MedImmune) is a therapeutic monoclonal antibody targeting PD-L1. Avelumab (also known as MSB0010718C; Merck KGaA, Darmstadt, Germany & Pfizer) is a fully human monoclonal PD-L1 antibody of isotype IgG1. BMS-936559 (also known as MDX-1105; Bristol-Myers Squibb) is a blocking antibody that has been shown to bind to PD-L1 and prevent its binding to PD-1 (see, e.g., USNIH clinical trial number NCT00729664). CA-170 (Curis, Inc.) is a small molecule PD-L1 antagonist. BMS-202, BMS-8, BMS-37, and BMS-242 are small molecule PD-1 / PD-L1 complex antagonists that bind to PD-1 (see, e.g., Kaz et al., (2016) Oncotarget 7(21); its disclosure is incorporated herein by reference in its entirety).Examples of anti-PD-L1 antagonists useful in the methods described herein, including antibodies, are not limited to those listed above, but include, for example, U.S. Patent Nos. 7,722,868, 7,794,710, 7,892,540, 7,943,743, 8,168,179, 8,217,149, 8,354,509, 8,383,796, 8,460,927, 8,552,154, and 8, Examples include those described in Patent Nos. 741,295, 8,747,833, 8,779,108, 8,952,136, 8,981,063, 9,045,545, 9,102,725, 9,109,034, 9,175,082, 9,212,224, 9,273,135 and 9,402,888, the disclosures of which are incorporated herein by reference in their entirety. Examples of anti-PD-1 antagonists useful in the methods described herein, including but not limited to these, include 6,808,710, 7,029,674, 7,101,550, 7,488,802, 7,521,051, 8,008,449, 8,088,905, 8,168,757, 8,460,886, 8,709,416, 8,951,518, 8,952,136, and 8,993,73 Examples include those described in 1, 9,067,998, 9,084,776, 9,102,725, 9,102,727, 9,102,728, 9,109,034, 9,181,342, 9,205,148, 9,217,034, 9,220,776, 9,308,253, 9,358,289, 9,387,247 and 9,402,899, the disclosures of which are incorporated herein by reference in their entirety.
[0101] Pharmaceutical preparations Pharmaceutical preparations of CIP compounds are also provided. CIP compounds can be incorporated into various formulations for administration to a subject. More specifically, the CIP compounds of the present invention can be formulated into pharmaceutical compositions in combination with suitable pharmaceutically acceptable carriers or diluents, and can be formulated into solid, semi-solid, liquid or gaseous preparations such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, and aerosols. Formulations can be designed for administration via several different routes, including oral, rectal, parenteral, intraperitoneal, intradermal, transdermal, intratracheal, and intravenous administration. In pharmaceutical dosage forms, the compounds can be used alone, or in appropriate association and combination with other pharmaceutically active compounds. The following methods and excipients are merely illustrative and not limiting.
[0102] Pharmaceutical compositions containing the active ingredient may be in forms suitable for oral use, such as tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to those skilled in the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents selected from the group consisting of sweeteners, flavoring agents, coloring agents, and preservatives in order to provide a pharmaceutically refined and palatable preparation. Tablets contain the active ingredient in mixture with non-toxic, pharmaceutically acceptable excipients suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating and disintegrating agents, such as corn starch or algin; binders, such as starch, gelatin, or acacia; and lubricants, such as magnesium stearate, stearic acid, or talc. Tablets may be uncoated, or they may be coated by known techniques to slow their disintegration and absorption in the gastrointestinal tract, thereby providing a sustained effect over a longer period. For example, time-delaying materials such as glyceryl monostearate or glyceryl distearate may be used. They may also be coated by techniques described in U.S. Patents 4,256,108, 4,166,452, and 4,265,874 to form osmotic therapeutic tablets for controlled release. Formulations for oral use may also be presented as hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate, or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with a water or oil medium, such as peanut oil, liquid paraffin, or olive oil.
[0103] The aqueous suspension contains the active substance in mixture with an excipient suitable for the preparation of the aqueous suspension. Such excipients may be suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, tragacanth gum, and acacia gum, and dispersing or wetting agents may be naturally occurring phosphatides such as lecithin, or condensation products of alkylene oxides and fatty acids such as polyoxyethylene stearate, or condensation products of ethylene oxide and long-chain aliphatic alcohols such as heptadecaethyleneoxycetanol, or condensation products of ethylene oxide and partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide and partial esters derived from fatty acids and hexitol anhydride such as polyethylene sorbitan monooleate. The aqueous suspension may also contain one or more preservatives, such as ethyl or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweeteners such as sucrose, saccharin, or aspartame.
[0104] Oily suspensions can be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil, or coconut oil, or in a mineral oil such as liquid paraffin. Oily suspensions may contain thickeners, such as beeswax, hard paraffin, or cetyl alcohol. Sweeteners and flavorings, such as those mentioned above, can be added to provide an oral preparation with a pleasant mouthfeel. These compositions can be preserved by adding antioxidants such as ascorbic acid.
[0105] Dispersible powders and granules suitable for preparing aqueous suspensions by adding water are mixed with a dispersant or wetting agent, a suspending agent, and one or more preservatives to provide an active ingredient. Suitable dispersants or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, such as sweeteners, flavoring agents, and coloring agents, may also be present.
[0106] The pharmaceutical compositions of the present invention may also be in the form of an oil-in-water emulsion. The oil phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as liquid paraffin, or a mixture thereof. Suitable emulsifiers may be naturally occurring phosphatides, such as soybeans and lecithin, and esters or partial esters derived from fatty acids and anhydrous hexitol, such as sorbitan monooleate, and condensation products of such partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweeteners and flavorings.
[0107] Syrups and elixirs may be formulated with sweeteners, such as glycerol, propylene glycol, sorbitol, or sucrose. Such formulations may also contain digestive agents, preservatives, and flavoring and coloring agents. Pharmaceutical compositions may also be in the form of sterile aqueous or oily suspensions for injection. These suspensions may be formulated according to known techniques using the preferred dispersants or wetting and suspending agents described above. Sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic, parenterally acceptable diluents or solvents, for example, as a solution in 1,3-butanediol. Acceptable vehicles and solvents available include water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixative oils have conventionally been used as solvents or suspension media. For this purpose, any mild fixative oil, including synthetic mono or diglycerides, may be used. In addition, fatty acids such as oleic acid have been found to be used in the preparation of injectable preparations.
[0108] The compounds can be formulated into injectable preparations by dissolving, suspending, or emulsifying them in aqueous or non-aqueous solvents such as vegetable or other similar oils, synthetic fatty acid glycerides, esters of higher fatty acids, or propylene glycol, and conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers, and preservatives may be used as needed. The compounds can be used in aerosol formulations administered by inhalation. The compounds of the present invention can be formulated in pressurized, acceptable propellants such as dichlorodifluoromethane, propane, or nitrogen.
[0109] Furthermore, the compounds can be made into suppositories by mixing them with various bases such as emulsifying bases or water-soluble bases. The compounds of the present invention can be administered rectally via suppositories. The suppositories may contain vehicles such as cocoa butter, carbowax, and polyethylene glycol that melt at body temperature but solidify at room temperature. The compounds of the present invention that are active by topical administration and their pharmaceutically acceptable salts can be formulated as transdermal compositions or transdermal delivery devices ("patches"). Such compositions may include, for example, a backing material, an active compound reservoir, a control membrane, a liner, and a contact adhesive. Using such transdermal patches, the compounds of the present invention can be continuously or discontinuously injected in controlled amounts. The construction and use of transdermal patches for drug delivery is well known in the art. See, for example, U.S. Patent No. 5,023,252 (issued June 11, 1991), which is incorporated in whole herein by reference. Such patches can be constructed for continuous, pulsed, or on-demand delivery of drugs.
[0110] Optionally, the pharmaceutical composition may contain other pharmaceutically acceptable components, such as buffers, surfactants, antioxidants, viscosity modifiers, and preservatives. Each of these components is well known in the art. See, for example, U.S. Patent No. 5,985,310, the disclosure of which is incorporated herein by reference. Other components suitable for use in the formulations of the present invention can be found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, Pa., 17th ed. (1985). In one embodiment, the aqueous cyclodextrin solution further comprises dextrose, for example, about 5% dextrose.
[0111] Dose levels on the order of approximately 0.01 mg to 140 mg / kg body weight per day are useful in typical embodiments, or alternatively, approximately 0.5 mg to 7 g per patient per day. For example, inflammation can be effectively treated by administering approximately 0.01 to 50 mg of the compound per kilogram of body weight per day, or approximately 0.5 mg to 3.5 g of the compound per patient per day. Those skilled in the art will readily understand that dose levels may vary depending on the specific compound, the severity of the symptoms, and the subject's sensitivity to side effects. The dosage of a given compound can be readily determined by those skilled in the art by various means.
[0112] The amount of active ingredient that may be combined with a carrier material to produce a single dosage form varies depending on the host being treated and the specific mode of administration. For example, a formulation intended for oral administration to humans may contain 0.5 mg to 5 g of the active ingredient combined with an appropriate and convenient amount of carrier material, which may vary from about 5% to about 95% of the total composition. Dosage units generally contain about 1 mg to about 500 mg of the active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
[0113] However, it will be understood that the specific dose level for any particular patient will depend on a variety of factors, including age, weight, general health, sex, diet, administration time, route of administration, excretion rate, drug combination, and the severity of the particular disease being treated. Therefore, unit dosage forms for oral or rectal administration, such as syrups, elixirs, and suspensions, may be provided, and each dosage form unit, e.g., one teaspoon, one tablespoon, a tablet, or a suppository, will contain a predetermined amount of the composition containing one or more inhibitors. Similarly, unit dosage forms for injection or intravenous administration may contain the inhibitor in the composition as a solution in sterile water, saline, or another pharmaceutically acceptable carrier. As used herein, the term “unit dosage form” refers to a physically distinct unit suitable as a unit dose for human and animal subjects, each unit containing a predetermined amount of the compound of the present invention calculated in sufficient quantity to produce the desired effect in conjunction with a pharmaceutically acceptable diluent, carrier, or vehicle. The specifications of the novel unit dosage forms of the present invention depend on the specific peptide mimetic compound used and the effect to be achieved, as well as the pharmacodynamics associated with each compound in the host.
[0114] Kits and Systems Kits and systems used in embodiments of the methods described above are also provided. As used herein, the term “system” refers to a collection of two or more different activators present in a single composition or in heterogeneous compositions, brought together for the purpose of practicing the subject method. The term “kit” refers to packaged activators (may be multiple). For example, kits and systems for practicing the subject method may comprise one or more pharmaceutical formulations. Thus, in a particular embodiment, a kit may comprise a single pharmaceutical composition existing as one or more unit dosage forms, and the composition may comprise one or more expression / activity inhibitor compounds. In yet another embodiment, a kit may comprise two or more distinct pharmaceutical compositions, each containing a different active compound.
[0115] In addition to the components described above, the subject kit may further include instructions for implementing the subject method. These instructions may be present in the subject kit in various forms, and one or more of them may be present in the kit. One form in which these instructions may be present is printed information on a suitable medium or on a circuit board, such as in the kit packaging or accompanying documents, for example, as one or more sheets of paper on which the information is printed. Another means may be a computer-readable medium on which the information is recorded, such as a diskette, CD, or portable flash drive. Yet another possible form may be a website address that can be used via the internet to access the information from a remote location. Any convenient means may be present in the kit. [Examples]
[0116] The following examples are presented as illustrations only and not as limitations.
[0117] experiment The following examples are provided to those skilled in the art to provide a complete disclosure and explanation of the methods of preparation and use of the present invention, and are not intended to limit the scope of what the inventors consider to be the invention, nor are they intended to represent that the following experiments are all or only experiments that can be performed. While efforts have been made to ensure accuracy of the figures used (e.g., quantities, temperatures, etc.), some degree of experimental error and deviation should be taken into consideration. Unless otherwise indicated, parts are by weight, molecular weight is weight-average molecular weight, temperature is in degrees Celsius, and pressure is atmospheric pressure or approximately atmospheric pressure.
[0118] I. CIP compounds for the treatment of ER-positive breast cancer by hijacking carcinogenic drivers A. Introduction In the United States, breast cancer is the cause of more than 40,000 deaths annually. Approximately one in eight women will develop breast cancer, and one in 39 will die from it. When surgery is ineffective in curing the cancer, several treatments are used, including hormone therapy, HER2 monoclonal antibodies, and immunotherapy. While each of these contributes to the effective treatment of breast cancer, many of the drugs used, such as anthracyclines, are nonspecific in their antitumor effects and therefore have broad toxicity that can be fatal. Thus, the field is seeking more specific pathways for treatment. Here, we describe a novel approach that results in more specific death of cancer cells compared to other cells, and therefore a better treatment with fewer side effects.
[0119] B. Overview The inventors have devised a general method for hijacking cancer-driving factors to activate cell death pathways, thereby killing cancer cells that induce driving mutations. In the specific case of breast cancer, the estrogen receptor (ER) and / or progesterone receptor (PR) are hijacked to activate PUMA, BIM, and other cell death genes. To do this, the inventors have invented small molecule proximity chemoinducers (CIPs) having estrogen-like compounds linked at the C17 or C7 position to ligands of transcription factors that normally bind to the regulatory regions of cell death genes such as PUMA, BAX, BIM, BID, and NOXA genes. Thus, the estrogen that normally drives tumors instead activates a set of genes, resulting in programmed cell death. This means that the breast cancer pathway that drives proliferation is hijacked to specifically kill cancer cells.
[0120] Many breast cancers are ER-positive and PR-positive. These hormone-responsive cancers are often treated with antagonists to these receptors, thereby reducing or slowing cancer growth. However, cancer is rarely successfully treated by drugs that simply reduce the rate of cancer growth, as it simply recurs when treatment is discontinued. Therefore, it is useful to divert the growth drivers of cancer to kill cancer cells. We have invented a series of molecules (CIPs) in which estrogen-like molecules at C17 are chemically bound to a small linker, which is then bound to ligands for transcription factors that control genes that induce apoptosis or programmed cell death, such as the PUMA, BIM, BAX, BID, and NOXA genes. These genes function downstream of p53 to initiate cell death when DNA damage occurs. In this way, these genes suppress cancer formation, which is one of the major effectors of the p53 tumor suppressor pathway. Many breast cancers have inactivated p53 and are therefore unable to respond to DNA damage signals that could eliminate cancer at the time of cancer development. In the embodiments described below, the transcription factor FOXO3a, which regulates the PUMA, BIM, and BAX genes, is selected. Figure 7 shows the means for defining the anchor transcription factor. While the approach using BIM is described, parallel experiments were performed for 10 other apoptosis-promoting genes.
[0121] A specific example of TF-CIP that may be used in such embodiments is estradiol linked to a small molecule binder of a transcription factor that activates programmed cell death genes. In other embodiments of the present invention, progesterone, one of several pro-apoptosis genes, and one of the following breast cancer selective transcription factors: 1) FOXO3A, 2) PPAR gamma, 3) HIF1A, 4) E2F1, 5) RUNX1, and MAZ are used, which bind to the promoters of other killer genes such as PUMA and BIM. Normally, estrogen binds to estrogen receptors and induces proliferation. In this embodiment of the present invention, a small molecule is used in which an estrogen receptor is bound to a transcription factor (TF) that binds to and modally activates killer genes, as a novel therapy for ER-positive breast cancer.
[0122] C. Specificity of TF-CIP in cancer One of the many advantages of this approach, which hijacks the cancer-driving factor pathway to activate the cell death pathway, is that it allows for the specific activation of killer genes and the cancer-driving factors themselves by utilizing the combination specificity of transcription factors. This is generally illustrated in Figure 7C, and the method is detailed in Figures 7A and B. The enhancement of specificity is then described as follows: (Selectivity of TF-A expression) x (Selectivity of cancer-driving factor expression) x (Genome specificity of TF-A) = Selectivity of cell death
[0123] There are many drugs and treatments used to treat human breast cancer, including hormone therapy, HER2 monoclonal antibodies, and immunotherapy, each of which has some degree of specificity to the tumor. There are also numerous drugs used for almost all metastatic breast cancers that have little to no specificity to cancer cells. Many of these simply stop the growth of cancer cells and other cells.
[0124] The advantage of our approach is that it utilizes the unique driving mechanisms of cancer to activate transcription factors that kill ER-positive breast cancer cells. A further advantage of our approach is that it can be modified to be highly specific to cancer cells. For example, if the estrogen receptor is expressed at a selective level of 6.5:1 in breast cancer cells, and the transcription factor bound to the cell death gene is expressed at a selective level of 10:1, breast cancer cells will be killed with 65-fold specificity, thereby establishing an effective therapeutic window. The therapeutic window can be predicted as follows: TIFF2023549132000005.tif10128In formula, [A1] is the concentration of the driving factor protein in cell type 1, [A2] is the concentration of the driving factor protein in cell type 2, [B1] is the concentration of anchor TF in cell type 1, [B2] represents the concentration of anchor TF in cell type 2.
[0125] D. Identification of transcription factors To identify transcription factors that can activate the expression of cell death genes, the inventors began by defining the cell death genes that were most effective in killing breast cancer cell lines. Using doxycycline-inducible expression, the inventors examined each of the cell death genes shown in Table 1 and found that some were effective in rapidly killing more than 50% of the cells. To identify transcription factor pairs that could be used to selectively activate these genes only in target cells, the inventors used the procedure outlined in Figures 7A, 7B, and 7C.
[0126] Next, the inventors attempted to identify transcription factors (TFs) with binding motifs within the ±1kb region surrounding the BIM TSS. This region contains chromatin accessible to TF binding, as revealed by analysis of ATAC-seq data from two patients randomly selected from the BRCA (Breast Invasive Carcinoma) cohort of the TCGA (Cancer Genome Atlas). The inventors' transcription factor identification method is stepwise described in Figure 7 and detected the presence of potential binding motifs for 337 TFs. The regulatory regions of BIM, BAX, and BID are also accessible in breast cancer cells and bind to overlapping TF groups, demonstrating that pro-apoptotic genes function synergistically, providing robust cell death when a single TF is activated. Therefore, several killer genes in breast cancer cells are vulnerable to transcriptional hijacking.
[0127] The inventors analyzed the expression of 337 selected TFs in five cancer cell lines using publicly available RNA-seq datasets. The list of TFs consistently showing high expression across cancer cell lines includes YBX1, ATF4, HIF1A, MAZ, NFE2L2, TGIF1, SMAD2, TFDP1, MYC, DDIT3, STAT3, PNRC2, HES1, FOXO3A, RUNX1, and PPARG. Among these TFs, RUNX1, HIF1A, PAX9, and PPARG are highly specific to breast tissue (according to the Human Protein Atlas). HIF1A is a master transcriptional regulator of the adaptive response to hypoxia and plays a crucial role in tumor angiogenesis and hypoxia-induced cell death.
[0128] E. Development of ligands for anchored transcription factors Our method for developing ligands to anchor TF is illustrated by the stepwise approach in Figure 8, which led to the identification of two classes of ligands for FOXO3A, shown in Figures 10 and 11.
[0129] F. Synthesis of estrogen-like ER binder-linker(n)-FOXO3a binder The TF-CIP shown below, i.e., the estrogen-like ER binder-linker(n)-FOXO3a binder, is synthesized as described below. The first component of the present invention, consisting of three parts (ALB hijackers), is an estrogen-like molecule including, but not limited to, those shown in Figure 20. These compounds are selected based on their ability to accommodate the linker at C17 and to retain activity and ER binding. C11 methoxy is used as part of the molecule because of its favorable binding and reported estrogenic activity.
[0130] The second component of CIP, consisting of three parts (ALB hijacker), is an n-carbon linker (L) designed to bridge the distance between the ER and the transcription factor (FOXO3a in this particular example). A suitable linker, such as the one described above, is used.
[0131] The third component of CIP, consisting of three parts (ALB hijackers), is a small molecule that binds to TF, which regulates the expression of cell death genes: PUMA, BAX, BID, and BIM. Figure 8 provides a systematic and stepwise approach to identifying ligands for key transcription factors, in this case FOXO3A. The ligands selected by this approach are shown in Figures 10 and 11. These molecules are the products of a stepwise process consisting of a structure-based virtual (in silico) screening using a Schrödinger glide of approximately 8 million flexible ligand drug-like compounds from a zinc library against the rigid crystal structure (PDB: 2uzk) of FOXO3a. The screening was performed by selecting an inflexible pocket from the crystal structure of FOXO3a and using this pocket for screening. Potentially toxic molecules and molecules predicted to have undesirable pharmacological properties were removed by manual correction, as shown in Figure 8.
[0132] Molecules of the general structure of ALB are tested for their ability to induce programmed cell death in estrogen-dependent cell lines such as MCF7 and MCF10 breast cancer cell lines. Hundreds of combinations of FOXO3A ligand (Figures 10 and 11), linker (e.g., as shown above), and estrogen analog (Figure 20) can be constructed and tested for their efficacy, but ten examples of bifunctional molecules are shown below. TIFF2023549132000006.tif123150
[0133] Using TF-CIP as shown in Figure 4, estrogen receptor-dependent cell death is observed, as shown in Figure 6, meaning that the oncogenic pathways driving these cells are bypassed to kill them. Cell death is determined to be dependent on the induction of PUMA, BAX, BIM, NOXA, and / or BID. In addition, the small molecule is tested for its ability to selectively kill estrogen-dependent cells in estrogen-independent cancer cells such as the breast cancer cell line MDA-MB-231, the kidney cell line HEK293, and the lymphocyte cell line Jurkat. Since estrogen receptors are expressed at approximately 6.5 times higher levels in primary breast cancer cells, cancer death is observed to be estrogen-dependent and relatively specific. The specificity of cell death is compared to other drugs used to treat breast cancer, such as adriomycin, etoposide, and other anthracycline-containing Topo II inhibitors, and cyclophosphamide.
[0134] This same approach is repeated for small molecules consisting of synthetic estrogens bound to small molecules that can bind to and activate cell death genes, including 1) MAZ; 2) PPAR gamma; 3) HIF2; 4) RUNX1; 5) E2F1, as well as others exemplified in Figure 8, including BIM, BAX, and BID.
[0135] G. Prediction of the development of drug resistance The inventors anticipate that resistance may arise for several reasons. For example, the binding site of the anchor TF may be mutated, or the TF may be mutated so that it no longer functions as an anchor. In this case, a second anchor is selected using the method provided in Figure 7, and the ligand for the anchor is defined using the method described in Figure 8. These ligands can then be used to construct another TF-CIP having an estrogen or progesterone analog (Figures 11 and 12) using established medicinal chemistry, which can be used as a second line of therapy if resistance develops. It is also possible that the estrogen receptor gene may be inactivated in response to therapy as part of a selective process of tumor development. Since this can only occur if another driving factor emerges (e.g., one of the drivers shown in Figure 14), the inventors construct a TF-CIP to hijack a new driver.
[0136] Another example of using TF-CIP as a way to address this potential complication involves constructing TF-CIP to recruit proteins with highly acidic domains to PUMA TSS. Acidic domains are known for their ability to activate transcription. To identify highly specific acidic proteins for breast tumors, the inventors used the following criteria: (1) an isoelectric point of less than 5; (2) the protein is either nuclear or cytoplasmic (in the latter case, it should have fewer than 500 amino acids to allow efficient transport to the nucleus); and (3) the average protein expression in tumors is at least four times greater than the expression in normal tissues. For this comparison, a gene expression database consisting of 1085 samples from BRCA TCGA patients and 291 samples from healthy individuals was used. The following 28 proteins were found to meet all three criteria: CENPF, CTXN1, DBNDD1, EPN3, ESRP1, FOXA1, GPRC5A, HN1, IFI6, KRT8, LMNB1, MCM4, MUC1, PKIB, PRC1, PRR15, PYCR1, RACGAP1, S100P, SDC1, SLC9A3R1, SPP1, STARD10, TFF1, TNNT1, TPD52, UBE2S, and ZWINT.
[0137] In the treatment of ER-negative cancers, progesterone receptors are targeted using a group of similar molecules based on progesterone analogs that hijack killer genes.
[0138] Synthetic method for H.ER-TF-CIP Scheme 1 TIFF2023549132000007.tif102128 Step 1. Preparation of Intermediate 1 A solution of 1-(5-chloro-4-((8-methoxy-1-methyl-3-(2-(methylamino)-2-oxoethoxy)-2-oxo-1,2-dihydroquinoline-6-yl)amino)pyrimidine-2-yl)piperidine-4-carboxylic acid (10 mg, 0.02 mmol, according to Reference 1) t-Boc-N-amide-PEG3-amine and (30 mg, 0.1 mmol), HATU (21 mg, 0.05 mmol), and DIPEA (50 μL, 0.4 mmol) in DMF (0.25 mL) was stirred at room temperature for 1 hour. The crude reaction product was purified by HPLC to obtain compound intermediate 1 (16 mg, 95%). MS observation [(M+H)+]: 805.9
[0139] Step 2. Preparation of Compound 1 A solution of intermediate 1 (16 mg, 0.02 mmol) was dissolved in DCM (1 mL), 0.2 mL of TFA was added, and the mixture was stirred at room temperature for 0.5 hours. The crude reaction product was purified by HPLC to obtain compound 1 (10 mg, 50%) as a white solid. MS observation [(M+H)+]: 705.8. TIFF2023549132000008.tif28150
[0140] Scheme 2 TIFF2023549132000009.tif167128 Step 1. Preparation of Intermediate 2 A solution of 2-((((13S,E)-3-hydroxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthrene-17-ylidene)amino)oxy)acetic acid (20 mg, 0.06 mmol, according to Reference 1)t-Boc-N-amide-PEG3-amine and (17 mg, 0.06 mmol), HATU (33 mg, 0.09 mmol), and DIPEA (33 μL, 0.2 mmol) in DMF (0.5 mL) was stirred at room temperature for 1 hour. The crude reaction product was purified by flash chromatography to obtain coupling product intermediate 2 (20 mg, 70%) as a white solid.
[0141] Step 2. Preparation of Intermediate 3 Intermediate-3 (60 mg, 0.1 mmol) was dissolved in 1 mL of DCM and exposed to 0.2 mL of TFA at room temperature for 0.5 hours. The crude reaction product was purified by HPLC to obtain compound intermediate 3 (30 mg, 60%). MS observation [(M+H)+]: 518.7
[0142] Step 3. Preparation of Compound 2 The solution of intermediate 3 (30 mg, 0.06 mmol), and 1-(5-chloro-4-((8-methoxy-1-methyl-3-(2-(methylamino)-2-oxoethoxy)-2-oxo-1,2-dihydroquinoline-6-yl)amino)pyrimidine-2-yl)piperidine-4-carboxylic acid (30 mg, 0.06 mmol, prepared according to WO2018 / 108704A1), HATU (38 mg, 0.1 mmol), and DIPEA (50 μL, 0.3 mmol) in DMF (1 mL) was stirred at room temperature for 1 hour. The crude reaction product was purified by HPLC to obtain compound 2 (10 mg, 50%) as a white solid. MS observation [(M+H)+]: 1031.1. TIFF2023549132000010.tif41150
[0143] Scheme 3 A solution of 3-(2-(2-(1-(5-chloro-4-((8-methoxy-1-methyl-3-(2-(methylamino)-2-oxoethoxy)-2-oxo-1,2-dihydroquinoline-6-yl)amino)pyrimidine-2-yl)piperidine-4-carboxamide)ethoxy)ethoxy)propanoic acid (7 mg, 0.009 mmol), DHT (6 mg, 0.018 mmol), EDCI (6 mg, 0.04 mmol), DMAP (5 mg, 0.018 mmol), and HOAt (5 mg, 0.009 mmol) in 0.25 mL of DMF was stirred at room temperature for 1 hour. The crude reaction product was purified by HPLC to obtain compound 3 (2 mg, 30%) as a white solid. MS observation [(M+H)+]: 963.1. TIFF2023549132000012.tif27150
[0144] compound 4 Compound 4 (TIFF2023549132000013.tif33128) was prepared according to the procedure in Scheme 1. MS observation [(M+H)+]: 699.8. TIFF2023549132000014.tif17149
[0145] compound 5 Compound 5 (TIFF2023549132000015.tif27128) was prepared according to the procedure in Scheme 2. MS observation [(M+H)+]: 1075.2. TIFF2023549132000016.tif29150
[0146] compound 6 Compound 6 (TIFF2023549132000017.tif28128) was prepared according to the procedure in Scheme 2. MS observation [(M+H)+]987.1: TIFF2023549132000018.tif32151
[0147] compound 7 Compound 7 (TIFF2023549132000019.tif40128) was prepared according to the procedure in Scheme 2. MS observation [(M+H)+]: 1025.3. TIFF2023549132000020.tif27149
[0148] compound 8 Compound 8 (TIFF2023549132000021.tif27128) was prepared according to the procedure in Scheme 2. MS observation [(M+H)+]: 955.1. TIFF2023549132000022.tif37150
[0149] Scheme 4. TIFF2023549132000023.tif711282-((((13S,E)-3-hydroxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthrene-17-ylidene)amino)oxy)acetic acid (15 mg, 0.06 mmol, according to reference 1)N-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)-1-(5-chloro A solution of -4-((8-methoxy-1-methyl-3-(2-(methylamino)-2-oxoethoxy)-2-oxo-1,2-dihydroquinoline-6-yl)amino)pyrimidine-2-yl)-N-methylpiperin-4-carboxamide (15 mg, 0.02 mmol, according to scheme 1), HATU (20 mg, 0.05 mmol), and DIPEA (50 uL, 0.3 mmol) in DMF (0.25 mL) was stirred at room temperature for 1 hour. The crude reaction product was purified by HPLC to obtain 9 (2 mg, 15%) as a white solid. MS observation [(M+H)+]: 1045.2. TIFF2023549132000024.tif41150
[0150] II. CIP compounds for regulating the expression of TPH2, the rate-limiting enzyme for serotonin synthesis. Methods for modulating cellular processes within different populations of neurons are necessary to elucidate the relationships between molecular mechanisms, circuits, and behaviors, and to develop cell-type or circuit-selective therapies for neurological disorders. We provide a novel, non-genetic, small-molecule-based method—Transcription Factor-Chemical Induction Proximity (TF-CIP)—that utilizes the cell-type and circuit specificity of endogenous transcription factors to modulate gene expression in a subset of neurons. TF-CIP utilizes a bifunctional small molecule to extract together an “anchor” transcription factor that naturally binds to a target gene and a “hijacked” transcription factor that enhances or represses the transcription of the target gene. Cell-type specificity is determined by the cross-expression of each transcription factor. Because the TF-CIP approach can be adapted to any organism and the transcription factors are well-conserved, it is reasonable to expect that the same TF-CIP small molecule can be used to modulate neuronal processes across animal species. The inventors use TF-CIP to modulate the expression of TPH2, the rate-limiting enzyme for serotonin synthesis, as a means of regulating serotonergic neurotransmission from a subset of serotonergic neurons (Figure 29, Panel A). Although the population of serotonergic neurons is relatively small, these neurons project throughout the brain and play a crucial role in regulating mood, anxiety, and social behavior (Figure 29, Panel A). Achieving circuit-level specificity for serotonin-modulating small molecules represents an improvement over current therapies, which often have undesirable side effects due to the indiscriminate targeting of serotonin signaling in the central and peripheral nervous systems. TPH2 expression is regulated by stress, sex hormones, and several transcription factors. The inventors are leveraging this knowledge, along with recently published single-cell RNA sequencing and projection mapping data of serotonergic neurons, as a resource for candidate TF-CIP transcription factors. Compared to genetically encoded tools for circuit-specific neural modulation, the small molecule TF-CIP method can be adapted relatively easily to cell-type and circuit-specific neural modulation in humans.
[0151] As an example, the construction and testing of TF-CIP in cells and animals to regulate the expression of TPH2, the rate-limiting enzyme for brain serotonin synthesis, are detailed. Briefly, this approach involves selecting a transcription factor (FEV) expressed only in serotonin-producing neurons of the TPH2 promoter, using the steps illustrated in Figures 7 and 9. Then, ligands for FEV are selected, as shown in Figure 17, using the method described in Figure 8. Molecules selected from the virtual screening have significant binding to the FEV protein, and in some cases to other ETS proteins, as measured using surface plasmon resonance (SPR). These bind chemically to linkers, on the one hand, as described above and illustrated in Figures 24A and 24B, and on the other hand, to ligands of transcription activators or repressors, which may include nBAF complexes, mainly defined by postmittal neuron-specific BAF53b (ACTL6B) and circuit-selective transcription factors such as PAX5 and BRD4. The loss of FEV results in a highly selective loss of TPH2 (PMID:12546819) expression, and since FEV is limited to central serotonin-producing neurons (PMID:10575032), the resulting TF-CIP is highly selective for serotonin production in the brain. Further details can be found in Appendix A of Priority Provisional Application No. 63 / 110,575 filed on November 6, 2020, the disclosures thereof are incorporated herein by reference.
[0152] III. CIP compounds for enhancing the expression of the haploinsufficiency gene ARID1B ARID1B (BAF250b) mutations are the most common cause of de novo intellectual disability and are often the cause of autism spectrum disorder (PMID:30349098). ARID1B is dose-sensitive, and loss of a functional mutation in one allele can cause intellectual disability, autism spectrum disorder, and / or Coffin-Siris syndrome. Therefore, doubling ARID1B expression would be therapeutic. We have shown that this can be done in human induced pluripotent stem cells (iPS cells) isolated from Coffin-Siris patients with loss of functional mutations in one allele and another normal allele. By recruiting a transcription activator to the promoter of the ARID1B gene, we differentiated iPS cells into neural precursors, resulting in normal ARID1B expression (Figure 26). This approach demonstrates that the absence of barriers to ARID1B expression in affected human neurons, and the introduction of transcription factors to its promoter, can cure or mitigate intellectual disability or autism in individuals with ARID1B haploinsufficiency.
[0153] To develop a TF-CIP that doubles the expression of ARID1B, we found that ARID1B is regulated by another autism transcription factor, TBR1, which binds to the ARID1B regulatory region and controls the transcription of this gene (PMID:27325115). Ligands for TBR1 are developed using the steps provided in Figure 8. TBR1 is a highly neuron-specific gene, providing selectivity for neurons, thereby avoiding targeted side effects and enhancing the therapeutic window. Ligands for TBR1 are bound to linkers as described above. These, on the other hand, bind to known ligands for transcription activators such as BRD4, nBAF, and PAX5 using chemical bonds well known to those skilled in the art.
[0154] IV. Methodology for designing TF-CIP with cell-specific activity Designing small molecule drugs with cell-specific activity is a central challenge in medicine. The relative lack of cell-specific drugs is one reason why many therapeutics are undesirable and sometimes have life-threatening side effects. A special feature of CIP molecules that can produce them with cell-specific activity is that they preferentially bind to both target proteins simultaneously. For example, the CIP molecule rapamycin binds to both of its target proteins, FRB and FKBP, with 20,000 times higher affinity than FRB alone (PMID:15796538). Therefore, CIP molecules are unlikely to function in cells that express only one of the target proteins. Thus, CIP molecules essentially encode cell specificity from the cross-relationship of the two target proteins.
[0155] This example describes a method for identifying cell-specific CIP transcription factor targets using single-cell gene expression data and statistical overlap and correlation analysis (see Figure 7A). First, the tissue of interest is dissected and isolated into single cells. RNA is extracted from the single cells, converted to cDNA, barcoded, and sequenced on a next-generation sequencer. After sequencing, the sequences are mapped to the genome and quantified. Individual cells are clustered according to the relevance of their gene expression profiles. In some embodiments, the desired cell type is indicated by the expression of endogenous cell-specific marker genes (e.g., FEV may be used as a marker for serotonergic neurons), while in other embodiments, transgenetic markers such as Cre recombinase, fluorescent proteins, or viral gene expression (e.g., retrograde markers for projection-specific neurons) may be used to indicate target cell clusters. In other embodiments, target cells may be purified before single-cell RNA sequencing (e.g., by fluorescence-activated cell sorting).
[0156] Two orthogonal approaches are used to identify co-expressed transcription factors in target cells: (1) Pearson correlation and (2) statistical duplication analysis. The Pearson correlation matrix represents the expression relationships between pairs of transcription factors across individual target cells. Transcription factor pairs showing positive (r>0.5) and significant (P<0.05) correlations are included in a list called Coexpressed_Target_TFs. To perform duplication analysis, a list of cells expressing a given transcription factor is generated and then analyzed using the geneOverlap package in R (Shen L, Sinai ISoMaM (2021). GeneOverlap: Testing and Visualizing Gene Duplication. R package version 1.30.0, http: / / shenlab-sinai.github.io / shenlab-sinai / ) to generate matrices representing odds ratios (measuring the intensity of duplication) and Jacquard indices (measuring the similarity between two lists) for all transcription factor pairs. Transcription factor pairs showing significant (P<0.05) duplication in expression are also added to the Target_TFs list.
[0157] Next, transcription factor pairs showing co-expression in non-target cells are excluded. This analysis uses single-cell RNA expression data from whole human tissues (e.g., the publicly available Single-Cell Atlas from the Human Protein Atlas). Where applicable, single-cell expression data from target cell types are excluded from this analysis. From this sub-dataset of non-target cells, single-cell expression data for each transcription factor expressed in target cells are extracted and analyzed by Pearson correlation and overlap analysis as described above. Transcription factor pairs that are not significantly correlated and do not overlap in their expression in non-target cells are added to the list Nontarget_TFs. The list of cell-specific transcription factor pairs is reduced because the lists Target_TFs and Nontarget_TFs overlap. Additional parameters that may cause transcription factor pairs to be excluded are a) the expression level of the transcription factor below a set threshold, b) the percentage of target cells expressing the transcription factor pair, and c) whether the binding motif of either transcription factor is present in a regulatory region near the target gene. Following this method, the inventors identified the following 14 pairs of transcription factors that exhibit selective co-expression in dopaminergic neurons of human substantia nigra: RORA:SOX6, RORA:AEBP2, AEBP:LCORL, PBX1:SETBP1, PBX1:PIAS1, PBX1:ZEB1, FOXP2:ZEB1, FOXP2:KLF12, MYT1L:ZNF91, ZFHX3:ZNF91, ZFHX3:ZNF420, ZNF91:ZNF420, AFF3:THRB, and TAX1BP1:TCF25. These transcription factors may function as targets for cell-specific CIP to enhance dopamine synthesis in patients with early-stage Parkinson's disease, as described in previous embodiments.
[0158] In at least some of the embodiments described above, one or more elements used in one embodiment may be interchangeably used in another embodiment unless such substitution is technically feasible. It will be understood by those skilled in the art that various other omissions, additions, and modifications may be made to the above methods and structures without departing from the scope of the claimed subject matter. All such modifications and changes are intended to be within the scope of the subject matter defined by the appended claims.
[0159] In general, the terms used herein, and in particular in the appended claims (e.g., the text of the appended claims), will be understood by those skilled in the art to be generally intended as “open” terms (for example, “including” should be interpreted as “including but not limited to,” “having” as “at least having,” and “includes” as “including but not limited to,” etc.). Where a certain number of introduced claim enumerations are intended, such intent will be explicitly enumerated in the claims, and where such enumeration is absent, such intent does not exist, will be understood by those skilled in the art to be further understood. For example, for the sake of understanding, the following appended claims may include the use of the introductory phrases “at least one” and “one or more” to introduce the claim descriptions. However, even if the same patent claim includes an introductory phrase such as “one or more” or “at least one,” and an indefinite article such as “one (a)” or “one (an),” the use of such phrases should not be interpreted as meaning that the introduction of a claim by the indefinite article “one (a)” or “one (an)” limits any particular patent claim containing such introduced claim to embodiments containing only one such description (for example, “one (a)” and / or “one (an)” should be interpreted as meaning “at least one” or “one or more”), and the same applies to the use of definite articles used to introduce claim descriptions. In addition, even if a particular number of introduced claim enumerations are explicitly enumerated, a person skilled in the art will recognize that such enumerations should be interpreted as meaning at least the number enumerated (for example, a bare enumeration of “two enumerations” without other modifiers means at least two enumerations, or two or more enumerations).Furthermore, when a convention similar to "at least one of A, B, and C, etc." is used, such a construction is generally intended to mean that a person skilled in the art would understand the convention (for example, "a system having at least one of A, B, and C" includes, but is not limited to, systems having A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or systems having A, B, and C together, etc.). When a convention similar to "at least one of A, B, or C, etc." is used, such a construction is generally intended to mean that a person skilled in the art would understand the convention (for example, "a system having at least one of A, B, or C" includes, but is not limited to, systems having A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or systems having A, B, and C together, etc.). It will be further understood by those skilled in the art that substantially any disjunct words and / or disjunct phrases presenting two or more alternative terms, whether in the specification, claims, or drawings, should be understood as intended to include the possibility of including one of the terms, either of the terms, or both of the terms. For example, the phrase “A or B” will be understood to include the possibility of “A” or “B” or “A and B.” In addition, if any feature or aspect of the present disclosure is described from the perspective of the Marcush Group, those skilled in the art will recognize that the present disclosure is also described from the perspective of any individual member of the Marcush Group, or any subgroup of members of the Marcush Group.
[0160] For all purposes, including providing written explanations, as will be understood by those skilled in the art, all scopes disclosed herein also encompass all possible sub-scopes and combinations thereof. Any listed scope can be readily recognized as sufficiently indicating and enabling that the same scope can be broken down into at least equal 1 / 2, 1 / 3, 1 / 4, 1 / 5, 1 / 10, etc. As a non-limiting example, each scope considered herein can readily be broken down into a lower third, a middle third, and an upper third, etc. As will be equally understood by those skilled in the art, all terms such as “maximum,” “at least,” “greater than,” “less than,” etc., include the number stated and refer to a scope that can be subsequently broken down into sub-scopes as described above. Finally, as will be understood by those skilled in the art, a scope includes each individual member. Thus, for example, a group having 1 to 3 articles refers to a group having 1, 2, or 3 articles. Similarly, a group having 1 to 5 articles refers to a group having 1, 2, 3, 4, or 5 articles, and so on.
[0161] Although the above inventions have been described in some detail by examples and illustrations for the sake of clear understanding, it will be readily apparent to those skilled in the art that certain changes and modifications can be made to these inventions in light of the teachings of the present invention without departing from the spirit or scope of the appended claims.
[0162] Therefore, the above merely illustrates the principles of the present invention. Those skilled in the art will understand that various arrangements embodying the principles of the present invention and falling within its spirit and scope can be devised, although not expressly described or shown herein. Furthermore, all examples and conditional language enumerated herein are primarily intended to help the reader understand the principles of the present invention and the concepts to which the inventors contribute to further the art, and should be construed as not being limited to such specifically enumerated examples and conditions. Moreover, all descriptions herein describing the principles, aspects and embodiments of the present invention, as well as their specific examples, are intended to encompass both their structural and functional equivalents. In addition, such equivalents are intended to include both currently known equivalents and equivalents to be developed in the future, i.e., any elements developed to perform the same function, regardless of their structure. Furthermore, nothing disclosed herein is intended to be publicly dedicated, whether such disclosure is expressly stated in the claims or not.
[0163] Accordingly, the scope of the present invention is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of the present invention are embodied in the appended claims. In the claims, Section 112(f) or Section 112(6) of the U.S. Patent Act is expressly defined as being referenced for the limitation in the claims only when the exact phrase “means for” or the exact phrase “steps for” is enumerated at the commencement of such limitation in the claims, and if such exact phrase is not used in the limitation in the claims, Section 112(f) or Section 112(6) of the U.S. Patent Act is not referenced.
Claims
1. A transcription factor-proximity chemical inducer (TF-CIP) for regulating the transcription of a target gene, the transcription factor-proximity chemical inducer (TF-CIP) comprising: (a) a first ligand that specifically binds to an endogenous anchor transcription factor in a cell, wherein the endogenous anchor transcription factor regulates transcription of a target gene in the cell; (b) a second ligand that specifically binds to an endogenous transcription factor in the cell; and Including, the first ligand and the second ligand are tethered by a linking moiety; and Through the TF-CIP-mediated binding event, the endogenous anchor transcription factor and the endogenous transcriptional regulator can spatially associate with each other such that the endogenous transcriptional regulator is recruited to regulate transcription of the target gene. Transcription factor-proximal chemical inducer (TF-CIP).
2. The TF-CIP described in claim 1, wherein the first ligand and the second ligand are small molecules.
3. TF-CIP described in claim 1 or 2, wherein the first ligand and the second ligand do not dissociate from each other under cellular conditions.
4. TF-CIP described in any one of claims 1 to 3, wherein the activity of the TF-CIP is cell type-specific.
5. The TF-CIP of claim 1, wherein the TF-CIP has a molecular weight of 2500 g / mol or less.
6. The TF-CIP of any one of claims 1 to 5, wherein the linking moiety comprises a linker, optionally, the linker covalently links the first ligand to the second ligand.
7. The TF-CIP of any one of claims 1 to 6, comprising a molecular adhesive.
8. TF-CIP described in any one of claims 1 to 7, wherein the cells are cancer cells.
9. A TF-CIP described in any one of claims 1 to 8, wherein the endogenous anchor transcription factor and the endogenous transcriptional regulatory factor are present primarily in the cell such that the TF-CIP exhibits highly selective activity for the cell.
10. TF-CIP according to any one of claims 1 to 9, wherein the endogenous transcriptional regulatory factor comprises a transcription factor.
11. A TF-CIP described in any one of claims 1 to 9, wherein TF-CIP-mediated ligation of the endogenous anchor transcription factor and the endogenous transcriptional regulatory factor reduces or enhances transcription of a target gene in the cell.
12. TF-CIP according to any one of claims 1 to 11, wherein the target gene is a pro-apoptotic gene.
13. TF-CIP described in claim 12, wherein the endogenous transcriptional regulatory factor is a carcinogenic transcription factor.
14. TF-CIP described in any one of claims 1 to 11, wherein the target gene is a therapeutically beneficial gene.
15. A composition for therapeutic use comprising TF-CIP according to any one of claims 1 to 14.
